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Abstract: 5-Membered N-heterocycles have become valuable structural motives in 
organometallic chemistry, organic synthesis, and medicinal chemistry. Such compounds 
can act as ligands for organometallic complexes and catalysts, as organocatalysts, and are 
structural components of many FDA-approved pharmaceuticals. We developed a new 
method for the synthesis of 1-aryl-4-substituted-triazolium salts, employing copper 
catalysis and diaryliodonium salts. Previously, 1-aryl-4-substituted-triazolium salts were 
synthesized by a multistep, low-yielding, synthetic pathway. Our arylation procedure 
progressed in two short steps, first, starting from cheap primary amines converting to the 
corresponding 4-substituted-1,2,4-triazoles, followed by the copper-catalyzed N-
arylation. The arylation of the 4-substituted-triazoles progressed under mild conditions, 
was tolerant of water and oxygen, and permitted a wide variety of functional groups in 
moderate to high yields. Further functionalization of our triazolium salts with amine 
substituents led to the discovery of an alternative approach to fused azoles. Bicyclic 
azoles were previously synthesized starting from a combination of hydrazonyl halide and 
thioether substituted azoles or starting from amino or hydrazinyl azoles. Our iodine-
promoted cyclization began from 4-(2-nitrophenyl)-1-substituted-4H-1,2,4-triazol-1-ium 
salts, which were all synthesized from 4-(2-nitrophenyl)-1,2,4-triazole using our arylation 
procedure and substitution reactions with high yields. Our nitro-containing triazolium 
salts were reduced and isolated as 4-(2-ammoniophenyl)-1-substituted-4H-1,2,4-triazol-
1-ium chlorides in high yields. Finally, subjecting the 4-(2-ammoniophenyl)-1-
substituted-4H-1,2,4-triazol-1-ium chlorides to iodine-promoted intramolecular 
cyclization allowed the synthesis of 9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 
salts in low to moderate yields. Our method allowed for a mild sequential synthesis of 
imidazo[2,1-c][1,2,4]triazol-1-ium salts from primary amines. Overall, we are confident 
that our procedure will allow access to novel organocatalysts and organometallic ligands, 
as well as compounds that exhibit biological activity. 
v 
 
TABLE OF CONTENTS 
 
Chapter          Page 
 
I. CHAPTER 1. INTRODUCTION ...............................................................................1 
 
 Section 1.0 Heterocycles in Chemistry ....................................................................1 
 Section 1.1 Heterocycles in Medicinal Chemistry ...................................................2 
 Section 1.2 N-Heterocyclic Carbenes ......................................................................7 
 Section 1.3 Application of 1,2,4-Triazolium Salts as Organocatalysts ...................8 
 Section 1.4 1,2,4-Triazolium Salts as Ligand Precursors for Transition Metal .....11 
                         Catalysts 
 Section 1.5 Synthesis of 1,3,4-Trisubstituted-1,2,4-triazolium Salts ....................13 
 Section 1.6 Synthesis of 1,4-Disubstituted 1,2,4-triazolium Salts .........................15 
 Section 1.7 Synthesis of Bicyclic Azoles ..............................................................18 
 Section 1.8 Overview .............................................................................................23 
 
 
II. CHAPTER 2. CATALYTIC PREPARATION OF 1-ARYL- SUBSTITUTED-...25 
                       1,2,4-TRIAZOLIUM SALTS 
  
 Section 2.0 Introduction .........................................................................................25 
 Section 2.1 Optimization and Substrate Scope of the ............................................27 
                    Copper Catalyzed Arylation 
 Section 2.2 Effects of Varying Reaction Parameters on Rate of Conversion ........35 
 Section 2.3 Conclusions .........................................................................................38 
    Section 2.4 General Procedures and Characterization Data for .............................39 
                    1,2,4-Triazoles (1a-1m) 
 Section 2.5 General Procedures and Characterization Data for .............................44 
                    1,4-Substituted-1,2,4-triazolium Salts 
 
III. CHAPTER 3. IODINE MEDIATED C–H ACTIVATION LEADING TO .........63 
                        BENZO[4,5]IMIDAZO[2,1-c][1,2,4]TRIAZOL-1-IUM SALTS 
 
 Section 3.0 Introduction .........................................................................................63 
 Section 3.1 Initial Formation of Benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium ...65 
                    Salts 
 Section 3.2 Synthesis of Starting Material for the Iodine-Promoted .....................66 
                    Intramolecular Cyclization 
 Section 3.3 Optimization of Iodine-Promoted Intramolecular Cyclization ...........68 





Chapter          Page 
 
III. CHAPTER 3. IODINE MEDIATED C–H ACTIVATION LEADING TO .........63 
                        BENZO[4,5]IMIDAZO[2,1-c][1,2,4]TRIAZOL-1-IUM SALTS 
 
 Section 3.5 Potential Mechanism for the Iodine-Promoted ...................................71 
                    Intramolecular Cyclization 
 Section 3.6 Conclusion ..........................................................................................72 
 Section 3.7 Procedure and Characterization Data for 4-(2-Nitrophenyl)- .............73 
                    [1,2,4]triazoles 
 Section 3.8 General Procedures and Characterization Fata for .............................74 
                    1-Substituted-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium Salts 
 Section 3.9 General Procedure, Analysis, and Characterization Data for .............81 
                    1-Substituted-(2-ammoniophenyl)-4H-1,2,4-triazol-1-ium Salts 
 Section 3.10 General Procedure and Characterization Data for ............................89 
                      9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium Salts 
 
IV. CHAPTER 4. CONCLUSION ..............................................................................96 
 




 APPENDIX A: GENERAL INFORMATION ....................................................113 
 APPENDIX B: COMMON ABBREVIATIONS ................................................114 
 APPENDIX C: INDEX OF MOLECULES AND STRUCTURES ....................116 
 APPENDIX D: SPECTRA FOR CHAPTER 2 ...................................................117 
  Section D.1: NMR Yields for 1,4-Substituted-1,2,4- Triazolium..................117 
                                 Salts (D001-D033) 
  Section D.2: Spectra for 1,4-Disubstituted-1,2,4-triazolium Salts ................134 
                       (D034-D107) 
 APPENDIX E: SPECTRA FOR CHAPTER 3 ....................................................171 
  Section E.1: Spectra for 4-(2-Nitrophenyl)-1,2,4-triazole (E001- E002) ......171 
  Section E.2: Spectra for 1-Substituted-4-(2-nitrophenyl)-4H-1,2,4- .............172 
                       triazol-1-ium Salts (E003-E023) 
  Section E.3: Spectra for 1-Substituted-(2-ammoniophenyl)-4H-1,2,4- .........183 
                       triazol-1-ium Salts (E024-E044) 
  Section E.4: Spectra for 9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium .193 






LIST OF TABLES 
 
 
Table           Page 
  
   Table 1. Optimization of the Copper Catalyzed Arylation .......................................28 
   Table 2. Synthesis of 4-Substituted-1,2,4-triazoles ..................................................29 
   Table 3. Scope of 1,2,4-Triazoles .............................................................................31 
   Table 4. Scope of Diaryliodonium Salts ...................................................................32 
   Table 5. Synthesis of 1-Mesityl-1,2,4-triazolium Salts ............................................34 
   Table 6. Variation of Steric and Electronic Parameters ............................................35 
   Table 7. Synthesis of 1-Substituted-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium .......67 
                 Salts 
   Table 8. Synthesis of 4-(2-Ammoniophenyl)-1-substituted-4H-1,2,4- ....................68 
                 triazol-1-ium Chlorides 
   Table 9. Optimization of Iodine-Promoted Intramolecular Cyclization ...................70 
   Table 10. Substrate Scope for the Iodine-Promoted Intramolecular Cyclization .....71
viii 
 
LIST OF FIGURES 
 
Figure           Page 
 
   Figure 1.  Examples of 5-Membered and 6-Membered Heterocycles ........................2 
   Figure 2.  Heterocycles in Nucleic Bases and Amino Acid ........................................3 
   Figure 3.  Examples of Heterocycle Containing FDA Approved Pharmaceuticals ....4 
   Figure 4.  Example of Triazole-Containing Bioactive Molecules in Literature .........5 
   Figure 5.  Examples of Biologically Active Fused Bicyclic Azoles...........................6 
   Figure 6.  1,2,4-Triazole Containing Transition Metal Complexes as........................6 
                   Anti-Cancer/Tumor Agents 
   Figure 7.  Stable N-Heterocyclic Singlet Carbenes from Substituted Azoles .............7 
   Figure 8.  Temperature Dependence of the Rate of Conversion of 1a .....................36 
   Figure 9.  Effects of Catalyst Loading on the Rate of Conversion of 1a ..................37 
   Figure 10. Effects of Varied Stoichiometry on the Rate of Conversion of 1a ..........38 
   
ix 
 
LIST OF SCHEMES 
 
Scheme          Page 
 
   Scheme 1. N-Heterocyclic Carbenes as Organocatalysts for the ................................8 
                    Benzoin Condensation 
   Scheme 2. NHC Catalyzed Stetter Reaction and Umpolung of Michael Acceptor ....9 
   Scheme 3. NHC Catalysis via the α,β-Unsaturated Acyl Azolium Intermediate .....10 
   Scheme 4. Bicyclic 1,2,4-Triazolium Salts as Ligands for  ......................................11 
                     Transition Metal Catalysts 
   Scheme 5. 1,4-Disubstituted-1,2,4-triazoles as Ligands for Transition Metal .........13 
                     Catalysts 
   Scheme 6. Synthesis of Enders Triazoles .................................................................14 
   Scheme 7. Synthesis of Bicyclic 1,3,4-Trisubstituted-1,2,4-triazolium Salts ..........15 
   Scheme 8. Synthesis of 1-Aryl-4-substituted-1,2,4-triazolium Salts via ..................16 
                     3-Aryl-1,3,4-oxidiazolium Salts 
   Scheme 9. Copper-Catalyzed Arylation of 1-Substituted-imidazoles using ............17 
                     Diaryliodonium Salts 
   Scheme 10. Catalytic N-Arylation of 1,2,4-Triazoles with Diaryliodonium Salts ...18 
   Scheme 11. General Synthesis of Bicyclic Azoles via Aryl Hydrazonyl Halides ....19 
   Scheme 12. Synthesis of 1,3-Disubstituted-1H-benzo[4,5]imidazo[2,1-c][1,2,4] ...20 
                       triazole 
   Scheme 13. Synthesis of Triazolo[3,4-c][1,2,4]triazole ...........................................20 
   Scheme 14. Synthesis of 1,2,4-Triazole Containing Bicyclic Azoles ......................21 
                       via Oxidative Cyclization 
   Scheme 15. Synthesis of Imidazo[2,1-c][1,2,4]triazoles via the Strecker Reaction .21 
   Scheme 16. Synthesis of Dihydroimidazo[2,1-c][1,2,4]triazoles .............................22 
   Scheme 17. Synthesis of Imidazo[2,1-c][1,2,4]triazoles Via ...................................22 
                       Acid-Promoted Cycilization 
   Scheme 18. Multicomponent Cyclization for the Synthesis of.................................23 
                       Imidazo[2,1-c][1,2,4]triazoles 
   Scheme 19. Preparation of 1-Aryl-4-substituted-4H-1,2,4-triazolium Salts ............26 
   Scheme 20. N-Arylation with Unsymmetrical Diaryliodonium Triflates .................32 
   Scheme 21. Previous Research on the C–H Activation of Azoles ...........................65 
   Scheme 22. Discovery of an Unexpected Cyclized Product.....................................65 
   Scheme 23. Plausible Mechanism for Iodine-Promoted Intramolecular ..................72  









Section 1.0 Heterocycles in Chemistry 
Heterocycles were first discovered in the early to mid-1800s.
1,2
 With few substantial 





 and organometallic chemistry.
9,11–14
 A heterocycle is 
defined as a cycle consisting of at least two different elements.
1
 In organic chemistry, 
these generally consist of one or more carbocycles with one or more oxygen, sulfur, or 
nitrogens in the cyclic structure. Examples of common aliphatic heterocycles are 1,4-
dioxanes, tetrahydrofuran, tetrahydropyran, and piperidine; common aromatic 
heterocycles are furan, pyridine, thiophene, pyrimidine, 1,2,4-triazole, and imidazole 
(Figure 1). When comparing cycles of like ring size and double bond substitution, 
heterocycles are very similar to carbocycles in their geometry and stabilities. However, 
heterocycles use their unshared pairs of electrons to coordinate, hydrogen bond, or act 




Many heterocycles are known as common solvents and bases, but their application expands 
to an astounding scale when incorporated into larger organic frameworks. 
Figure 1. Examples of 5-Membered and 6-Membered Heterocycles  
 
Section 1.1. Heterocycles in Medicinal Chemistry 
In medicinal chemistry, heterocycles have essential functions both within our body and as 
components of drug molecules.
1,15
 Within humans, DNA and RNA’s function is dependent 
on the sequence of the nucleic acids adenine, thymine, guanine, and cytosine (Figure 2), 
which are all aromatic heterocycles.
1
 The ribose sugar linker, as it appears in our RNA, is an 
oxygen-containing aliphatic heterocycle. The three amino acids proline, tryptophan, and 
histidine are N-heterocycles necessary for many biological processes.
1
 Heterocycles are 
essential pharmacophores in various commercial drugs capable of eliciting a biological 





Figure 2. Heterocycles in Nucleic Bases and Amino Acid 
 
Some heterocycles are found throughout FDA-approved pharmaceuticals and are considered 
potent pharmacophores and useful structural motives.
16
 The Njardarson group analyzed the 







 Their analysis revealed that the 2012 FDA database contained 1086 
unique small-molecule drugs, of which 640 (59%) contained at least one N-heterocycle,
5
 and 
208 (19%) contained at one or more sulfurs in the structure.
4
 Their review of the 2017 
database for O-heterocycles found 311 (27%) unique O-heterocycles from the list of 





Figure 3. Examples of Heterocycle Containing FDA Approved Pharmaceuticals  
 
A sample of FDA-approved pharmaceuticals is depicted in Figure 3, displaying the potential 
range of applications from antihistamines to antidepressants and even chemotherapeutics.
3,5
 
Reviewing the 2012 and 2017 FDA pharmaceutical databases revealed that many 
pharmaceuticals contain multiple heterocycles, with the most common being 5- and 6-
membered heterocycles.
3,5
 The bioactivity of heterocycle-containing small molecules sparked 
several research groups to investigate the isolation, synthesis, and biological activity of 
potential drug candidates along with previously established pharmaceuticals.
17–20
 Recently, 
there has been significant advances in the synthesis of various substitutions of azoles. 1,2,4-
Triazoles (highlighted structure in Figure 1) will be the primary focus of this dissertation. 
Though not as abundant, research into the small molecules containing 5-membered azoles 
has revealed potential drug candidates containing 1,2,4-triazoles and imidazole displaying 
similar biological potencies as shown by several FDA-approved pharmaceuticals.
21–24
 Figure 
4 depicts a sample of recently investigated 1,2,4-triazole-containing bioactive molecules 




 as well as 
promising activities that could lead to an anti-Parkinson’s agent.
29
 1,2,4-Triazoles and 
5 
 
derivatives have shown a wide range of biological applications, including anti-inflammatory, 
analgesic, anti-convulsant, antioxidant, anti-migraine, diuretic, and muscle relaxants, 
displaying the broad applicability of 1,2,4-triazoles and N-heterocycles in general.
2
 
Figure 4. Examples of Triazole-Containing Bioactive Molecules in Literature 
 
In pharmaceuticals, fused polycyclic systems are abundant. The Njardarson group stated that 
in the 2012 FDA pharmaceutical database, 14% of unique nitrogen-containing small drug 
molecules contained fused rings.
5
 The medicinal chemistry field has echoed this notion with 
a recent increase in research on the synthesis and biological activity of fused nitrogen-
containing aromatic heterocycles.
30–36
 Shown in Figure 5 are samples of biologically active 





 and anti-tumor/cancer agents.
39
 Research into the biological 











Figure 5. Examples of Biologically Active Fused Bicyclic Azoles 
 
The biological activity of transition metal complexes containing 1,2,4-triazole ligands has 




Figure 6. 1,2,4-Triazole Containing Transition Metal Complexes as Anti-Cancer/Tumor 
Agents 
 
The deprotonation of the 1,2,4-triazolium salts precursors results in N-heterocyclic carbene 









 as depicted in Figure 6. 1,2,4-Triazolium, imidazolium, and thiazolium salts form N-
7 
 
heterocyclic carbenes (Figure 7a),
9,11
 which have applications as organocatalysts beside their 
uses as ligands for transition metal catalysts/complexes.
8,12,13,38
 
Section 1.2: N-Heterocyclic Carbenes 
Figure 7. Stable N-Heterocyclic Singlet Carbenes from Substituted Azoles 
 
Carbenes are reactive intermediates characterized by an uncharged carbon atom with two 
non-bonded electrons. Carbenes can exist in either the singlet or triplet form. Singlet 
carbenes are characterized by a lone pair of electrons occupying an sp
2
 hybridized orbital on 
an uncharged carbon atom with an empty p orbital (Figure 7b), allowing singlet carbenes to 
potentially act either nucleophilicly or electrophilicly. In contrast, triplet carbenes are 
characterized by two unpaired electrons, one occupying the sp
2
 hybridized orbital and one in 
the unhybridized p orbital, displaying reactivity similar to di-radicals. The deprotonation of 
substituted azolium salts results in a stable singlet carbene (Figure 7a).
11
 One reason for this 
reactivity is the stabilization of the empty p-orbital by overlapping with the filled p-orbitals 
of adjacent heteroatoms (Figure 7b).
11
 This understanding allows for a better-educated design 




Section 1.3: Application of 1,2,4-Triazolium Salts as Organocatalysts  
A well-known reaction catalyzed by N-heterocyclic carbenes is the benzoin condensation 
(Scheme 1a).
7
 The NHC catalyzed benzoin condensation progresses through the umpolung of 
an aldehyde, forming a “Breslow intermediate”, which is nucleophilic and can attack an 
electrophile, such as an aldehyde, and form the product after deprotonation and subsequent 
dissociation of the catalyst (Scheme 1b). 
Scheme 1.  N-Heterocyclic Carbenes as Organocatalysts for the Benzoin Condensation  
 
Scheme 1c depicts samples of chiral catalysts which were found to catalyze the benzoin 
condensation with good to excellent enantioselectivity (>82% ee).
7
 Another NHC catalyzed 
reaction is the Stetter reaction which involves a Michael acceptor as the electrophile for the 
Breslow intermediate, resulting in a 1,4-dioxo species (Scheme 2a). The Enders group 
9 
 
showed that their novel catalyst was capable of catalyzing the Stetter reaction in moderate to 
high yields (43-98%) with moderate to good enantioselectivity (56-87%).
49
 NHCs can also 
be used to umpolung a Michael acceptor; Fischer and coworkers proved that with a variation 
of the Enders triazole it is possible to promote an intramolecular β-alkylation of Michael 
acceptors in good to high yield (64-94%). Moreover, a variety of leaving groups and 
electron-withdrawing groups were tolerated (Scheme 2b).
50
 
Scheme 2. NHC Catalyzed Stetter Reaction and Umpolung of Michael Acceptor  
 
Another organocatalytic application of NHCs is the functionalization of α,β-unsaturated 
aldehydes via the α,β-unsaturated acyl azolium intermediate.
10
 This intermediate accentuates 
the electrophilic properties of the β-position and the carbonyl carbon (Scheme 3b,c),
51,52
 
while also allowing the α-position to act as a nucleophile (Scheme 3a).
53
 The examples 
depicted in Scheme 3 describe research by Biju, Enders, and Bode using the same chiral 
catalyst to perform different reactions through the α,β-unsaturated acyl azolium intermediate. 
The Biju group outlined the synthesis of different cyclopentenes in low to moderate yields 
(40-85%) with excellent enantioselectivity (>90% ee). They proposed that the β-position of 
the α,β-unsaturated acyl azolium intermediate was attacked first by the enolate formed 
between the 1,3-ester groups. This was followed by an attack on the aryl ketone by the 
10 
 
enolate formed at the α-position from the attack at the β-position, with an elimination to form 
the final product (Scheme 3a).
53
 Research by Enders and coworkers described a 1,3-addition 
to α,β-unsaturated aldehydes by a substituted benzothiazole in moderate to high yields (43-
91%) with low to moderate enantioselectivity (32-73% ee) (Scheme 3b).
51
 Finally, the Bode 
group published an alternative 1,3-addition of the α,β-unsaturated aldehyde using a 
substituted enol as the nucleophile. This reaction proceeded with good to high yields (74-
98%) and moderate to high enantioselectivity (68-99% ee) (Scheme 3c).
52
 These examples 
are not an exhaustive list of the potential organocatalytic applications for N-heterocyclic 
carbenes, as there are many others described in the literature.
8,54
  




Section 1.4. 1,2,4-Triazolium Salts as Ligand Precursors for Transition Metal Catalysts 
N-Heterocyclic carbenes are well-known as ligands for transition metal complexes.
12–14
 An 
N-heterocyclic carbene is considered a strong σ-donor with the potential to act as a π-
acceptor.
9,11
 The substituents on the N-heterocyclic carbene have a steric effect on the metal 
complex and an electronic effect on the metal center, allowing for tunable alteration to the 
selectivity and efficiency of transition metal catalysts.
12,14
 Bao and coworkers catalyzed the 
substitution of an allylic carbonate ester employing an iridium complex formed in situ from a 
bicyclic achiral 1,2,4-triazolium salt pre-catalyst and an iridium salt.
55
 Through variation of 
the R-substituent on the allylic carbonate ester, they found that aromatic substituents favored 
Product a (85-99 % yield), and alkyl substituents favored Product b (84% yield) (Scheme 
4a).
55
 The Feringa group performed a catalytic arylation of an allylic bromide with aryl 
lithium reagents, for which they used a chiral bicyclic 1,2,4-triazole copper(I) catalyst.
56
 




Scheme 4. Bicyclic 1,2,4-Triazolium Salts as Ligands for Transition Metal Catalysts 
 
Scheme 5 depicts three examples of the application of 1,4-substituted-1,2,4-triazole 
complexes. The Kuhn group demonstrated that their bidentate rhodium(I) complex could 
12 
 
promote the hydrogenation of α,β-unsaturated esters with a high ee, up to 61% (Scheme 
5a).
57
 The Choudhury group demonstrated their ruthenium(I) complex containing a bidentate 
triazole ligand caused olefins and alkynes to oxidize to ketones/aldehydes and 1,2-diones, 
respectively.
58
 A comparison between related imidazole and 1,2,4-triazole catalysts indicated 
that the 1,2,4-triazole catalyst was superior (52-92% yields) to the analogous imidazole 
complex (2-58% yields).
58
 Finally, the Darcel group reported a borylation reaction catalyzed 
by a nickel(I) complex (Scheme 5c), for which high conversions (71-98%) but low isolated 
yields were reported (8-40%).
59
 In summary, transition metal complexes bearing carbene 
ligands are effective catalysts for a large range of reactions. Further examples include aryl-
aryl cross-coupling reactions, aryl C–H activations, olefin metathesis, chiral conjugate 






Scheme 5. 1,4-Disubstituted-1,2,4-triazoles as Ligands for Transition Metal Catalysts 
 
 
Section 1.5. Synthesis of 1,3,4-Trisubstituted-1,2,4-triazolium Salts 
The broad application of the 1,2,4-triazole motif in catalysts, ligand, and bioactive molecules 
is a strong motivation to develop new pathways for their synthesis. 1,3,4- and 1,4-
substituted-triazolium salts (Scheme 6-11) are common substitution patterns for catalyst or 
ligand precursors. The triazole ring is formed in the last step in the standard synthesis of 1-
aryl-3,4-substituted-1,2,4-triazolium salts. The desired compounds can be made from an aryl 
hydrazine, a single carbon electrophilic species (HCO2H, HC(OEt)3), and a precursor capable 
of a nucleophilic acyl substitution followed by an imine condensation.
61–63
 A well-known 
14 
 
1,2,4-triazolium salt used in organocatalysis is the Enders catalyst. The Enders group 
synthesized this catalyst precursor from benzoyl chloride by first forming the N-phenyl 
benzamide followed by a thionyl chloride activated imine condensation to form N,N'-
diphenylbenzohydrazonamide in 58% yield.
61
 The cyclization is initiated using formic acid 
as a single carbon electrophile and acetic anhydride as a dehydrating agent, with a strong acid 
such as perchloric acid necessary to form the 1,3,4-triphenyl-1,2,4-triazolium perchlorate in 
77% yield (Scheme 6).
61
 By substituting either the amine or the aryl hydrazine in the first 
step, it is possible to tune the resulting carbene catalyst’s reactivity and selectivity. For 
example, when the Fisher group utilized 4-methoxyphenyl substituents as replacements for 




 position, higher yields were observed in the 




Scheme 6. Synthesis of Enders Triazoles  
 
The synthesis of bicyclic 1-aryl-3,4-substituted-1,2,4-triazolium salts begins with a cyclic 
amide starting material, first undergoing an alkylation using trimethyloxonium 
tetrafluoroborate to form the protonated imine ester in situ (Scheme 7).
62
 This undergoes a 
nucleophilic acyl substitution by aryl hydrazine which is then cyclized using 
triethoxymethane as the single carbon electrophile to form the desired 1,2,4-triazolium salts. 
The yields obtained by this approach vary significantly and depend on the exact aryl 
15 
 
hydrazine and the original amide chosen for this reaction. The Rovis group synthesized 
examples of chiral and achiral bicyclic 1,2,4-triazolium salts (Scheme 7). For their synthesis 
of the achiral bicyclic 1,2,4-triazolium salts, good yields were observed (74-76%) (Scheme 
7a),
62,63




Scheme 7. Synthesis of Bicyclic 1,3,4-Trisubstituted-1,2,4-triazolium Salts  
 
Section 1.6. Synthesis of 1,4-Disubstituted-1,2,4-triazolium Salts 
1,4-Disubstituted-1,2,4-triazolium salts are synthesized by different methods depending on 
the nature of the N-substituents. The synthesis of 1-alkyl-4-substituted-1,2,4-triazolium salts, 
where the substituent can be aryl or alkyl, only required a substitution reaction of a 4-
substituted-1,2,4-triazole or 4H-1,2,4-triazoles with an alkyl halide to access the 1-alkyl-4-
substituted-1,2,4-triazolium halide or 1,4-dialkyl-1,2,4-triazolium halide, respectively.
64
 The 
synthesis of 1-aryl-4-substituted-1,2,4-triazolium salts is more difficult, requiring the 
exchange of oxygen in 3-aryl-1,3,4-oxadiazolium salts for the nitrogen of a primary amine 
(Scheme 8a).
65–70
 Depending on the aryl group, the synthesis and use of these 3-aryl-1,3,4-
oxadiazolium salts can be problematic as yields vary significantly depending on the aryl 
16 
 
substitution. The use of perchloric acid in this synthesis poses a safety hazard that should not 
be neglected. Scheme 8b and Scheme 8c describe two examples of the synthesis of 1-phenyl-
4-substituted-1,2,4-triazolium salts using 3-phenyl-1,3,4-oxadiazolium perchlorate. The 
Connon group attempted to form a chiral 1-aryl-4-alkyl-1,2,4-triazolium salt under 
anhydrous conditions but could not isolate the product with yields greater than 6%.
68
  
Scheme 8. Synthesis of 1-Aryl-4-substituted-1,2,4-triazolium Salts via 3-Aryl-
1,3,4-oxadiazolium Salts 
 
However, Connon and coworkers showed that this catalyst had excellent enantioselectivity 
(99% ee) for the benzoin condensation but were unable to isolate the product in yields above 
33%.
68
 The Schmidt group successfully formed their 1-phenyl-4-substituted-1,2,4-triazolium 
salts in higher yields (60-62%) (Scheme 8c). They prepared various sulfur, selenium, borate 
mono-dentate, and bidentate adducts incorporating this triazolium unit in moderate yields.
65
 
A completely different pathway to these compounds could procced via the arylation of a 
17 
 
1,2,4-triazole precursor. The copper-catalyzed N-arylation of 4H-1,2,4-triazoles was first 
reported using aryl iodides in the presence of CuO nanoparticles.
71
 Recently, an alternative 
copper-catalyzed arylation method was reported using a soluble copper salt catalyst with 
diaryliodonium salts as an arene source.
72–75
 Lv and coworkers were the first to use 
symmetrical diaryliodonium salts to synthesize diaryl N-heterocyclic carbene precursors 
from 1-substituted-imidazoles.
72
 They were able to arylate imidazoles containing aliphatic 









The same group also reported a direct N-arylation of unsubstituted imidazoles and 1,2,4-
triazoles to give the N,N-diarylimidazolium salts in 41-82% yield and the corresponding 
1,2,4-triazolium salts in 38-69% yields (Scheme 10a).
73
 The Kumar group arylated the N
1
 
position of [1,2,4]triazolo[4,3-a]pyridine using symmetrical diaryliodonium salts in good to 
excellent yields (75-95%) (Scheme 10b).
74
 These developments offer the potential for rapid 
catalyst optimization since it is known that the N
4
 substituent will dominate the electronics of 
organocatalysts. These methods allow for late-stage N-arylation of N-heterocycles, which 
previously had yet to be conducted on 4-substituted-1,2,4-triazoles until in 2019 when the 
Bolliger group reported the copper-catalyzed arylation of various 4-substituted-1,2,4-
triazoles with simple diaryliodonium salts (Chapter 2).
75
  
Scheme 10. Catalytic N-Arylation of 1,2,4-Triazoles with Diaryliodonium Salts 
 
Section 1.7. Synthesis of Bicyclic Azoles  
To reiterate from Section 1.1, several FDA-approved pharmaceuticals contain fused 
heterocycles, such as 1H-imidazo[2,1-c][1,2,4]triazoles and 1H-[1,2,4]triazolo[3,4-
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c][1,2,4]triazoles. These fused aromatic heterocycles have been synthesized over the years in 
various ways.
76
 Currently a common method for the synthesis of 1H-imidazo[2,1-
c][1,2,4]triazoles and 1H-[1,2,4]triazolo[3,4-c][1,2,4]triazoles employs hydrazonyl halides 
and methylthio-substituted azoles initially forming the amidrazone intermediate A, which 
cyclizes in situ with concurrent elimination of CH3SH to form the desired product B (Scheme 
11).
77
 Depicted in Scheme 12 and Scheme 13 are three related examples of the synthesis of a 
1,2,4-triazole ring in fused bicyclic systems utilizing substituted hydrazonyl halides. 
Scheme 11. General Synthesis of Bicyclic Azoles via Aryl Hydrazonyl Halides 
 
 Al-Omair and coworkers used 2-(methylthio)-1H-benzo[d]imidazole and a simple 
hydrazonyl bromide to form their imidazo[2,1-c][1,2,4]triazole in a yield of 80% (Scheme 
12a).
77
 Testing its biological activity revealed strong activity against a variety of Gram-
positive and Gram-negative bacteria.
77
 Abdelhamid and coworkers synthesized their 
respective imidazo[2,1-c][1,2,4]triazole using 2-(methylthio)-1H-benzo[d]imidazole and a 






Scheme 12. Synthesis of 1,3-Disubstituted-1H-benzo[4,5]imidazo[2,1-c][1,2,4]triazole 
 
The Shawali group elected to use a 3-thiomethyl-5-phenyl-1,2,4-triazole and a (Z)-N-
phenylbenzohydrazonoyl chloride to synthesize 1H-[1,2,4]triazolo[3,4-c][1,2,4]triazole, 
formed in 75% yield (Scheme 13). Upon testing the biological activity of this compound, 
they discovered that it was effective as an anti-microbial agent.
79
  
Scheme 13. Synthesis of Triazolo[3,4-c][1,2,4]triazole 
 
Imidazo[2,1-c][1,2,4]triazole can be synthesized from amino or hydrazinyl substituted 
azoles. The Demmer group started from hydrazinyl azoles, first forming the imine and then 
cyclizing using PhI(OAc)2 as an oxidant. Utilizing this method, it was possible to prepare 
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various examples of thiazolo[2,3-c][1,2,4]triazoles, oxazolo[2,3-c][1,2,4]triazoles, and 
imidazo[2,1-c][1,2,4]triazoles in up to 82% yields (Scheme 14).
80
 
Scheme 14. Synthesis of 1,2,4-Triazole Containing Bicyclic Azoles via Oxidative 
Cyclization 
 
More recently, Sadek and coworkers used a microwave-assisted Strecker reaction to form 
their variation of imidazo[2,1-c][1,2,4]triazole from 3-amino-1,2,4-triazole, an aldehyde, and 
benzoyl cyanide (Scheme 15). Using high temperatures and short reaction times, they 
isolated the products in 80-85% yields.
81
  
Scheme 15. Synthesis of Imidazo[2,1-c][1,2,4]triazoles via the Strecker Reaction 
 
 The Sztanke group synthesized dihydroimidazo[2,1-c][1,2,4]triazoles using 2-
hydrazineylidene-1-methylimidazolidine and carboxylic acid as starting materials (Scheme 
16). The amide forms first followed by an intramolecular imine condensation, generating 
their desired product in 43-70% yields.
39
 Testing the biological activity of their substrates, 
they discovered that a few exhibited both anti-tumor and anti-microbial activity. 
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Scheme 16. Synthesis of Dihydroimidazo[2,1-c][1,2,4]triazoles 
 
Aouali and coworkers used two different methods to synthesize their imidazo[2,1-
c][1,2,4]triazole substrates. Starting from 5-amino-substituted triazoles and α-bromoketones, 
they synthesized several 1-phenyl-3,5-substituted-imidazo[2,1-c][1,2,4]triazole in moderate 




Scheme 17. Synthesis of Imidazo[2,1-c][1,2,4]triazoles Via Acid-Promoted Cycilization 
 
In their second approach, Aouali and coworkers used scandium triflate as the Lewis acid to 
promote the multicomponent cyclization to access N-substituted-1-phenyl-3,6-substituted-






Scheme 18. Multicomponent Cyclization for the Synthesis of Imidazo[2,1-
c][1,2,4]triazoles 
 
Section 1.8. Overview  
For years, 1,2,4-triazoles have been less common in medicinal chemistry, organic synthesis, 
and organometallic chemistry, with imidazoles and thiazoles having a higher abundance in 
all three fields. Advances in the synthesis of 1,2,4-triazole-containing systems are likely to 
make 1,2,4-triazole based structural motifs more attractive. When attempting to prepare 
specific 1,4-disubstituted-1,2,4-triazolium salts for a different project, the Bolliger group 
discovered that some of the desired substitution patterns were impossible to obtain via 
traditional synthetic routes. We predicted that a copper-catalyzed arylation could be used to 
arylate 4-substituted-1,2,4-triazoles utilizing diaryliodonium salts as an aryl source and that 
this alternative method would allow us to access various 1,4-disubstituted-1,2,4-triazolium 
salts quickly. We determined that this would be a valuable tool for the synthesis of potential 
organocatalysts and ligands. During the synthesis of an amine-containing triazolium salt via 
reduction of a nitro group, we discovered the formation of a benzo[4,5]imidazo[2,1-
c][1,2,4]triazolium salt byproduct. While these reductive conditions resulted in a mixture of 
products, we hypothesized that oxidative conditions would allow us better control over the 
reaction and lead to the exclusive formation of benzo[4,5]imidazo[2,1-c][1,2,4]triazolium 
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salts. We believe this method provides an alternative synthetic route to a potentially 
biologically active motif. Our work can bridge gaps in this highly competitive field and, 
additionally, allows rapid diversification, modification, and tuning of potential aryl-









CATALYTIC PREPARATION OF 1-ARYL-SUBSTITUTED-1,2,4-TRIAZOLIUM SALTS 
 
Section 2.0 Introduction  
In the literature, 1,2,4-triazolium salts are well established as precursors to N-heterocyclic 
carbenes (NHC’s), with applications as organocatalysts (Schemes 1-3)
8,83–88
 and ligands 
for transition metal catalysts/complexes (Schemes 4,5).
55–58,88,89
 Furthermore, 
phosphorescent cyclometalated complexes have been synthesized containing 1,2,4-
triazole based ligands, where varied substitution allowed for tunable emission 
wavelengths.
90–92
 In medicinal chemistry, 1,2,4-triazoles are proven pharmacophores in 
natural products and are present in several FDA-approved pharmaceuticals.
16
 When 







 and also shows 
activity against cancer (Figure 4).
101–104
 When incorporated into late transition metal 
complexes, 1,2,4-triazole ligands have shown in vitro anticancer activity against breast, 
cervical, colon, liver, lung, and skin cancers and have displayed anticancer activity 
against leukemia (Figure 6).
45–48,105
 Some 1,2,4 triazolium salts have exhibited 





Previously, the syntheses of 1-aryl-substituted-1,2,4-triazolium salts were carried out via 
a three-step process, forming an oxadiazolium intermediate from an aryl hydrazine in two 
steps, then using a primary amine to form the 1,2,4-triazole ring (Schemes 8,19).
65,67–69
  
Scheme 19. Preparation of 1-Aryl-4-substituted-4H-1,2,4-triazolium Salts 
 
This synthetic method has a limited functional group tolerance and is potentially 
hazardous to synthesize on large scales. The oxadiazolium perchlorate intermediate is 
extremely water-sensitive and utilizes perchloric acid in its synthesis. Second, apart from 
phenylhydrazine, aryl hydrazines are expensive when purchased and can decompose and 
release nitrogen gas rapidly under certain conditions. Third, while the synthesis of the 
phenyl oxadiazolium intermediate was not problematic and formed in nearly quantitative 
yield, the 3-mesityl-1,3,4-oxadiazolium intermediate synthesized from the mesityl 
hydrazine proved troublesome (8% yield). An alternative route to form 1,4-diaryl- and 1-
aryl-4-alkyl-1,2,4-triazolium salts had to be investigated to expand our research. We 
decided to begin with primary amines, which are readily available and relatively 
straightforward to synthesize. The amines are first converted to the 4-substituted-4H-
1,2,4-triazoles, followed by an N-arylation using diaryliodonium salts and a copper 
catalyst to obtain the 1,4-disubstituted triazolium salts. Diaryliodonium salts are well 
established in the literature as arylation reagents for oxygen and nitrogen nucleophiles, 
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which can be catalyzed by various copper salt/complexes.
107–109
 Chen and coworkers 
described a copper-free route to N-aryl pyridinium species from pyridinium N-oxides or 
sulfonamidates and diaryliodonium salts.
110,111
 However, a copper catalyst was required 
for the N-arylation of pyridines.
112,113
 Kumar and coworkers investigated fused triazolium 
salts utilizing a copper-catalyzed N-arylation of [1,2,4]triazolo-[4,3-a]pyridines (Scheme 
10b).
74
 The preparation of 4-aryltriazolium or 3-arylimidazolium salts via similar 
methods has been reported previously (Schemes 9,10a).
72,73,114–122
 To our knowledge, 
examples of the copper-catalyzed 1-arylation of monocyclic triazoles with 
diaryliodonium salts have not been described in the literature. 
Section 2.1: Optimization and Substrate Scope of the Copper Catalyzed Arylation 
Mild conditions and shorter reaction times were driving factors for optimizing the 
copper-catalyzed arylation. Initially, on a 0.5 mmol scale, we began optimizing the 
copper-catalyzed 1-arylation of 4-substituted-4H-1,2,4-triazoles utilizing the substrates 
4-benzyl-4H-1,2,4-triazole (1a) and diphenyliodonium tetrafluoroborate, which was 
conducted in sealed microwave tubes, monitored by LCMS (Table 1). In the presence of 
all copper(I) and copper(II) catalysts, except CuI, we found that >95% conversion to 2a 
was achieved after 4 h at 100 °C in DMF and acetonitrile while reactions in water 
required longer reaction times (entries 1−13). Varying copper(I) versus copper (II) salts 
in acetonitrile at 80 °C, we observed that after 4 h, CuOAc achieved 100% conversion 
and that anhydrous Cu(OAc)2 and Cu(OAc)2·H2O achieved 87% and 88% yields, 
respectively (entries 14−16). These results suggest that copper(I) is superior under these 
conditions. We also observed that this reaction proceeded with no unexpected byproducts 
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when monitored by LCMS or NMR. Without a copper catalyst, a conversion of 17% 
(entry 17) was observed after 4 h.  
Table 1. Optimization of the Copper Catalyzed Arylation 
a) 
 
Entry Cu Catalyst 
Catalyst 
Loading 
Solvent Temperature Time 
Conversion 
c) 
1 Cu(OAc)2.H2O 5 mol% DMF 100 °C 4h >95% 
2 Cu(OAc)2 5 mol% DMF 100 °C 4h >95% 
3 Cu(OAc) 5 mol% DMF 100 °C 4h >95% 
4 d) Cu(OAc)2 5 mol% H2O 100 °C 4h >80% 
5 d) Cu(OAc) 5 mol% H2O 100 °C 4h >80% 
6 Cu(OAc)2.H2O 5 mol% MeCN 100 °C 4h >95% 
7 Cu(OAc)2 5 mol% MeCN 100 °C 4h >95% 
8 Cu(OAc) 5 mol% MeCN 100 °C 4h >95% 
9 Cu(OTf)0.5 Tol 5 mol% MeCN 100 °C 4h >95% 
10 Cu(TC) 5 mol% MeCN 100 °C 4h >95% 
11 Cu(OTf)2 5 mol% MeCN 100 °C 4h >95% 
12 Cu(acac)2 5 mol% MeCN 100 °C 4h >95% 
13 CuI 5 mol% MeCN 100 °C 4h <30% 
14 Cu(OAc)2.H2O 5 mol% MeCN 80 °C 4h 88% 
15 Cu(OAc)2 5 mol% MeCN 80 °C 4h 87% 
16 Cu(OAc) 5 mol% MeCN 80 °C 4h ~100% 
17 None  MeCN 80 °C 4h 17% 
18 Cu(OAc)2.H2O 5 mol% MeCN 80 °C 1h 80% 
19 Cu(OAc)2 5 mol% MeCN 80 °C 1h 79% 
20 Cu(OAc) 5 mol% MeCN 80 °C 1h 97% 
a) 
Reaction conditions: triazole 1a (0.5 mmol), Ph2IBF4 (1.5 equiv.), Cu catalyst (relative 
to 1a), solvent (2 mL), and reaction time. 
b) 
Relative to 1a. 
c) 
Conversion based on LCMS 
analysis. 
d) 
After 18 h, >95% conversion. 
 
A shortened reaction time of 1 hour resulted in 97% conversion when CuOAc was used 
as the catalyst. However, using anhydrous Cu(OAc)2 and Cu(OAc)2·H2O as catalysts 
resulted in significantly lower conversions when subjected to these shorter reaction times 
(entries 18−20). We decided that CuOAc was the most efficient and least expensive 
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catalyst for the arylation reaction at 80 °C in acetonitrile. Investigation of the scope of the 
copper-catalyzed N-arylation began with 4-substituted-4H-1,2,4-triazoles (1a−1m), 
which were synthesized from their corresponding 1° amines with yields ranging from 
7.4% to 74% (Table 2).
64,123–128
  
Table 2: Synthesis of 4-Substituted-1,2,4-triazoles  
 
a) Reaction conditions: primary amine (1.0 equiv), N,N-dimethylformylamide azine 2·HCl (1.5 
equiv), neat, 24 h, 150 °C. 
b) Reaction conditions: primary amine (1.0 equiv), 
N,N-dimethylformylamide azine 2·HCl (1.5 equiv), layered with xylenes, 24 h, 150 °C. 
We subjected 1a-1m to our previously optimized arylation conditions using 
diphenyliodonium tetrafluoroborate as the aryl source. Our findings are summarized in 
Table 3. Using NMR analysis, we found that 100% conversion was observed for all 
4-substituted-4H-1,2,4-triazoles (1a−1m), and the arylation products (1-phenyl-4-
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substituted-4H-1,2,4-triazolium salts 2a−2m) were all obtained in good to excellent 
yields (Appendix D, Figures D001−D014) with no other arylation products. Simple alkyl 
(2a−2c), aryl (2d and 2e), and haloaryl substituents (2g−2k) were arylated in good yields. 
The copper-catalyzed arylation of 1f yielded 2f without any arylation of the para-
methoxy-substituted sulfide. Similarly, 1l and 1m formed 2l and 2m preferentially 
despite containing several heteroaryl nitrogen atoms that could have been arylated. No 
other possible arylation products were observed under the optimized reaction conditions. 
Generally, the isolated yields were within 5−10% of the predicted NMR yields. However, 
we observed significantly lower isolated yields for the heteroaryl-substituted-triazolium 
salts (2l, 2m). Interestingly 2l appeared to be strongly retained on silica, while 2m 
decomposed on silica and required recrystallization. Aryl substitution at the N
1
-position 
of 1,2,4-triazolium salts affected the ring’s electronics when used for organocatalytic 
transformation, making easy late-stage arylation which is of general interest for the 
organic community. Varying the diaryliodonium salts (Table 4), we began investigating 
the scope of the copper-catalyzed quaternization using triazole 1d as the control. Testing 
diaryliodonium tetrafluoroborates and triflates, we observed 100% conversion of starting 
material after 4 hours of reaction time forming 1-aryl-4-phenyl-triazolium salts 
preferentially (2d−9d). Electron-poor (e.g., 7d) and unhindered electron-rich (e.g., 6d) 
aryl groups were examined and gave high yields. However, the introduction of ortho-
substituted aryl groups (3d−5d) resulted in decreased isolated yields. Interestingly, 
product 9d could not be isolated with LCMS, but indicated complete consumption of 
starting material, through 
1
H NMR and 
19
F NMR data were inconclusive when searching 
for the presence of the perfluoro arylated product. 
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Reaction conditions: triazoles 1a−1m (1.0 mmol), Ph2IBF4 (1.5 mmol), CuOAc (0.05 
mmol, 5 mol%), MeCN (4 mL), 80 °C, and 4 h. 
b) 
Conversion based on NMR analysis. 
c) 
NMR yield as determined by 
1












Reaction conditions: triazole 1d (1.0 mmol), Ar2IBF4 or Ar2IOTf (1.5 mmol), CuOAc 
(0.05 mmol, 5 mol%), MeCN (4 mL), 80 °C, and 4 h. 
b) 
Conversion based on NMR 
analysis. 
c) 
NMR yield as determined by 
1





Conversion determined by LCMS. 
 
Scheme 20. N-Arylation with Unsymmetrical Diaryliodonium Triflates 
 
As an alternative method to obtain and isolate 9d, it was questioned whether 





 Unfortunately, we found that only traces of the desired compound 9d 
were detected while 5% of the side product 4d was isolated. The remaining components 
consisted of unreacted starting materials, including the unreacted 
mesityl(perfluorophenyl)iodonium triflate. When using mesityl(phenyl)iodonium triflate, 
instead of mesityl(perfluorophenyl)iodonium triflate for the N-arylation, we found the 
more electron-deficient aryl group was transferred preferentially, giving 2d with 95% 
selectivity.
107
 Unsymmetrical diaryliodonium salts have the potential to form two 
different arylation products. In our case, we found with the formation of 2d came in 
tandem with the formation of 4d, and separation by column chromatography was only 
possible on a small scale (Scheme 20). Preparing symmetrical diaryliodonium salts 
avoids the problematic separation, making them the preferable iodonium salts to perform 
the N-arylation of triazoles. We were interested in applying our N-arylation method to 
synthesize 1-mesityl-substituted-1,2,4-triazolium salts 4a−4l (Table 5), due to our low 
yields observed via the traditional route (Scheme 19a). We observed that for all reactions, 
complete conversion was obtained, but isolated yields were generally lower for each 
substrate compared to the corresponding phenyl derivatives (Table 3). A possible 
explanation could be the difficulty of separating the desired product from the remaining 









Reaction conditions: triazoles 1a−1l (1.0 mmol), Mes2IOTf (1.5 mmol), CuOAc (0.05 
mmol, 5 mol%), MeCN (4 mL), 80 °C, and 4 h. 
b) 
Conversion based on NMR analysis. 
c)
 
NMR yield as determined by 
1
H NMR analysis relative to mesitylene as the internal 
standard. 
d)
 Isolated yield; 1 mmol scale. 
e)
 Isolated yield; 8 mmol scale. 
 
Upon scaling up the catalytic reaction for various substrates (e.g., with 4c), we observed 
increased yields for challenging substrates, as recrystallization became a potential 
alternative purification method. The copper-catalyzed quaternization of 4-substituted-4H-
1,2,4-triazoles 1a−1m allows for varying electronic and steric parameters in an efficient 
and systematic route. The preparation of unsymmetrically substituted electron-rich 
carbene precursors (3j and 5b) and sterically hindered electron-poor 1,2,4-triazolium salts 
(7e and 8e) gave high yields (Table 6). The electron-rich pyrimidine derivative 6m 
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formed cleanly, but required recrystallization to purify. Our reaction conditions proved to 
be an ideal method for the N-arylation of 4-substituted-4H-1,2,4-triazoles within short 
reaction times. To gain deeper insight into this reaction’s limitations, parameters such as 
temperature, catalyst loading, and stoichiometry of the diaryliodonium salt were varied 
(Figures 8-10). 





 Reaction conditions: triazoles 1a−1m (1.0 mmol), Ar2IBF4 or Ar2IOTf (1.5 mmol), 
CuOAc (0.05 mmol, 5 mol%), MeCN (4 mL), 80 °C, and 4 h. 
b)
 Conversion based on 
NMR analysis. 
c)
 NMR yield as determined by 
1
H NMR analysis relative to mesitylene as 
the internal standard. 
d)
 Isolated yield; 1 mmol scale. 
e)
 Isolated yield; 3 mmol scale. 
 
Section 2.2. Effects of Varying Reaction Parameters on Rate of Conversion  
To better understand the N-arylation’s temperature dependence, we ran four 0.5 mmol 
scale reactions using 1a as our triazole and diphenyliodonium tetrafluoroborate as our 
aryl source. Keeping a consistent reaction temperature at 25 °C, 40 °C, 60 °C, and/or 80 
°C for the four reactions and taking LCMS samples at varying time intervals, we 
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monitored the conversion of the starting material 1a. We found that lowering the reaction 
temperature below 60 °C decreased the rate of conversion significantly, with prolonged 
reaction times necessary to achieve complete conversion (Figure 8). 





Similar to the temperature variation experiments, four reactions were completed keeping 
the temperature constant at 80 °C and lowering the catalyst loading from 5 mol% to 0.5 
mol% and without catalyst. We monitored the reaction at the same time intervals. As 
expected, we found that lower rates of conversion occurred with lower catalyst loading in 
the first hour. However, reaction progress was not altered, with complete conversion 
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addition of a copper catalyst, quaternization still occurred at 80 °C, but at a significantly 
lower rate with 82% conversion obtained after 23 h (Figure 9).  





To determine the optimal stoichiometric ratio of the diaryliodonium salt, we ran four 
reactions decreasing the loading of diphenyliodonium tetrafluoroborate from 1.5 
equivalents to 1.0 equivalent. Complete conversion of the starting material was obtained 
after 4 hours when the reaction contained 1.5 equivalents of  the iodonium salt, but 1.25 
and 1.1 equivalents required six-hour reaction times to achieve complete conversion 
(Figure 10). When 1.0 equivalent of iodonium salt was added, 24 h was necessary to 
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We propose a Cu(I)/Cu(III) mechanism for the N-arylation of 1,2,4-triazoles in analogy 
to the related literature.
74,107,129
 Our findings that the copper(I) salt proved to be more 
efficient than the corresponding copper(II) salt at promoting the N-arylation was in 
agreement with this mechanism. 
 
Section 2.3. Conclusions 
In summary, we have developed an efficient and selective method for the synthesis of 
1-aryl-4-substituted-4H-1,2,4-triazolium salt via a copper-catalyzed arylation of 






0 1 2 3 4 5 6
Variation of Stoichiometry 

















stage arylation of 1,2,4-triazoles in high yields using cheap and safe reagents under mild 
reaction conditions and without the need for oxadiazolium perchlorate intermediates. We 
now have access to novel 1-aryl-4-substituted-4H-1,2,4-triazolium salts that were 
previously difficult to obtain, thus opening new avenues of research for applications of 
1,2,4-triazoles in transition metal complexes, as organocatalysts, and in medicinal 
chemistry.   
Section 2.4: General Procedures and Characterization Data for 1,2,4-Triazoles 
(1a-1m) 
General Procedure Ia for the Synthesis of Triazoles 1a−1m.  
The amine (1 equiv) and the dihydrochloride of N,N-dimethylformylamide azine (1.5 
equiv) were ground together in a mortar until the mixture liquefied or became a 
homogeneous solid. It was then transferred to a round-bottom flask equipped with a stir 
bar. The flask was fitted with a reflux condenser, the atmosphere of the system was 
exchanged for argon, and the reaction was heated in an oil bath to 150 °C for 16 h. After 
cooling to room temperature, the reaction mixture was basified with 1 M NaOH and then 
was extracted with DCM (3 × 100 mL). The combined organic phase was washed with 
water (2 × 50 mL), dried (MgSO4), filtered, and concentrated. The crude product was 
purified by column chromatography (5% methanol in DCM) or by precipitation from a 






General Procedure Ib for the Synthesis of Triazoles 1a−1m. 
 The amine (1 equiv), the dihydrochloride of N,N-dimethylformylamide azine (1.5 equiv), 
and para-toluenesulfonic acid (0.05 equiv) were ground together in a mortar until the 
mixture liquefied or became a homogeneous solid and then was transferred to a round-
bottomed flask equipped with a stir bar. The reaction mixture was suspended in xylenes, 
a reflux condenser was placed on the round-bottomed flask, and the mixture was heated 
under argon in an oil bath to 150 °C for 16 h. After cooling to room temperature, the 
crude product was purified as described in procedure Ia. 
 
Reaction/Structural Data of Formed 1,2,4 Triazoles. 
4-Benzyl-4H-1,2,4-triazole (1a). 
 The title compound was prepared on a 50 mmol scale according to general procedure Ib. 
Purification by column chromatography (silica, 5% methanol in DCM) yielded the 
product as a colorless solid in 42% yield (3.31 g, 20.8 mmol). The measured analytical 





The title compound was prepared on a 100 mmol scale according to general procedure Ib. 
The product was precipitated with hexanes from a concentrated DCM solution which 
gave the pure pale-yellow solid in 15% yield (2.19 g, 14.5 mmol). The measured 








 The title compound was prepared on a 100 mmol scale according to general procedure 
Ib. The crude product was dissolved in a minimal amount of 5% methanol in DCM and 
precipitated with toluene which gave the pure product as a colorless solid in 31% yield 






 The title compound was prepared according to general procedure Ib on a 50 mmol scale. 
The pure light brown solid was obtained by precipitation with hexanes from a 
concentrated solution of DCM. Yield: 73% (5.29 g, 36.5 mmol). The measured analytical 




4-(2,6-Diisopropylphenyl)-4H-1,2,4-triazole (1e).  
The title compound was prepared according to general procedure Ia on a 50 mmol scale. 
Purification by column chromatography (silica, 5% methanol in DCM) yielded the 
product as an off-white solid in 37% yield (4.20 g, 18.3 mmol). The measured analytical 





 The title compound was prepared in 69% yield according to a literature procedure on a 
100 mmol scale.
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 The title compound was prepared on a 25 mmol scale according to general procedure Ia. 
Purification by column chromatography (silica, 5% methanol in DCM) yielded the 
product as an off-white solid in 48% yield (1.96 g, 12.0 mmol). 
1
H NMR (400 MHz, 
CDCl3, 298 K): 8.49 (s, 2H), 7.55-7.50 (m, 1H), 7.23-7.14 (m, 3H); 
13
C{1H} NMR (100 
MHz, CDCl3, 298 K): δ = 163.3 (d, JC-F = 250.7 Hz), 141.3, 135.1 (d, JC-F = 9.7 Hz), 
132.0 (d, JC-F = 9.1 Hz), 117.9 (d, JC-F = 3.5 Hz), 116.2 (d, JC-F = 21.0 Hz), 110.1 (d, JC-F = 
25.2 Hz); 
19
F{1H} NMR (376 MHz, CDCl3, 298 K, referenced to C6H5F): δ = -110.21.  
 
4-(3-Fluorophenyl)-4H-1,2,4-triazole (1h). 
 The title compound was prepared on a 25 mmol scale according to general procedure Ia. 
Purification by column chromatography (silica, 5% methanol in DCM) yielded the 
product as a pale-yellow solid in 26% yield (1.04 g, 6.38 mmol). 
1
H NMR (400 MHz, 
CDCl3, 298 K): δ = 8.35 (d, JC-F = 1.5 Hz, 2H), 7.50-7.43 (m, 2H), 7.34-7.30 (m, 2H); 
13
C{1H} NMR (100 MHz, CDCl3, 298 K): δ = 154.3 (d, JC-F = 250.1 Hz), 142.3 (d, JC-F = 
2.3 Hz), 130.8 (d, JC-F = 7.7 Hz), 125.2, 122.0 (d, JC-F = 12.3 Hz), 117.6 (d, JC-F = 19.3 
Hz); 
19
F{1H} NMR (376 MHz, CDCl3, 298 K, referenced to C6H5F): δ = -123.56.  
 
4-(4-Fluorophenyl)-4H-1,2,4-triazole (1i). 
 The title compound was prepared on a 25 mmol scale according to general procedure Ia. 
Purification by column chromatography (silica, 5% methanol in DCM) yielded the 
product as an off-white solid in 28% yield (1.16 g, 7.1 mmol). 
1
H NMR (400 MHz, 
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CDCl3, 298 K): δ = 8.45 (s, 2H), 7.43-7.38 (m, 2H), 7.28-7.22 (m, 2H); 
13
C{1H} NMR 
(100 MHz, CDCl3, 298 K): δ = 162.6 (d, JC-F = 250.1 Hz), 141.8, 130.0 (d, JC-F = 11.0 
Hz), 132.4 (d, JC-F = 3.6 Hz), 124.5 (d, JC-F = 8.8 Hz), 117.4 (d, JC-F = 23.4 Hz); 
19
F{1H} 
NMR (376 MHz, CDCl3, 298 K, referenced to C6H5F): δ = -110.10.  
 
4-(2-Chlorophenyl)-4H-1,2,4-triazole (1j).  
The title compound was prepared on a 25 mmol scale according to general procedure Ia. 
Purification by column chromatography (silica, 5% methanol in DCM) yielded the 
product as an off-white solid in 51% yield (2.31 g, 12.9 mmol). 
1
H NMR (400 MHz, 





(100 MHz, CDCl3, 298 K): δ = 142.9, 131.5, 131.3, 131.2, 129.9, 128.5, 127.6.  
 
4-(4-Chlorophenyl)-4H-1,2,4-triazole (1k). 
 The title compound was prepared on a 25 mmol scale according to general procedure Ia. 
Purification by column chromatography (silica, 5% methanol in DCM) yielded the 
product as an off-white solid in 34% yield (1.51 g, 12.0 mmol). 
1
H NMR (400 MHz, 




H} NMR (100 MHz, CDCl3, 298 K): δ = 141.5, 135.2, 132.4, 130.6, 123.7.  
 
2-(4H-1,2,4-Triazol-4-yl)pyridine (1l).  
The title compound was prepared on a 50 mmol scale according to general procedure Ia. 
Purification by column chromatography (silica, 5% methanol in DCM) yielded the 
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product as a pale-yellow solid in 30% yield (2.22 g, 15.2 mmol). The measured analytical 





 The title compound was prepared on a 100 mmol scale according to general procedure 
Ib. Purification by column chromatography (silica, 5% methanol in DCM) yielded the 
product as a pale-yellow solid in 7.4% yield (1.09 g, 7.4 mmol). The measured analytical 




Section 2.5: General Procedures and Characterization Data for 1,4-Substituted-
1,2,4-triazolium Salts  
General Procedure IIa for the Catalytic Arylation of Triazoles 1a−1m. 
 A 10 mL Schlenk flask equipped with a stir bar was loaded with the triazole (1 mmol, 
1.0 equiv), diaryliodonium salt (1.5 mmol, 1.5 equiv), and copper(I) acetate (0.05 mmol, 
5 mol%) and sealed with a PTFE screwcap and filled with argon through septa on 
sidearm. Dry acetonitrile (4 mL) was added under a stream of argon, and the flask was 
resealed, then placed into an oil bath where the solution was stirred for 4 h at 80 °C. After 
the reaction mixture was cooled to room temperature, the solvent was evaporated. 
Calculated yields and conversions from NMR analysis were determined by the addition 
of mesitylene (1 mmol, 1 equiv) in DMSO-d6 to the crude reaction mixture. The pure 






General Procedure IIb for the Catalytic Arylation of Triazoles 1a−1m. 
 A 5 mL microwave tube equipped with a stir bar was loaded inside a glovebox with the 
triazole (0.5 mmol, 1.0 equiv) and the diaryliodonium salt (0.75 mmol, 1.5 equiv). After 
sealing the microwave tube and removing it from the glovebox, the catalyst (copper(I) 
acetate (0.025 mmol 0.05 equiv, 5 mol%) in 2 mL of acetonitrile) was added via syringe 
to the reaction mixture. The mixture was then stirred for 4 h in an oil bath at 80 °C, 
cooled to room temperature, and concentrated. Calculated yields and conversions from 
NMR analysis were determined by the addition of mesitylene (0.5 mmol, 1 equiv) in 
DMSO-d6 to the crude reaction mixture. The pure triazolium salts were obtained either by 
recrystallization or column chromatography (DCM/acetone, 4:1) as described below. 
4-Benzyl-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2a]BF4). 
 The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM 2. DCM/acetone 4:1, Rf = 0.28) yielded the 
product as an off-white solid in >99% yield (161 mg, 0.498 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 10.98 (s, 1H), 9.52 (s, 1H), 7.92 (d, J = 7.7 Hz, 2H), 7.72-7.68 
(m, 2H), 7.64 (t, J = 7.3 Hz, 1H), 7.56 (d, J = 7.6 Hz, 2H), 7.50-7.44 (m, 3H), 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 145.0, 141.8, 135.0, 
133.2, 130.6, 130.2, 129.1, 129.0, 128.8, 120.8, 51.0. HRMS (ESI) calcd, [C15H14N3]
+
 
236.1182; observed, 236.1171.  
 
4-Cyclohexyl-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2b]BF4).  
The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.33) yielded the 
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product as an off-white solid in 90% yield (141 mg, 0.449 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 10.86 (s, 1H), 9.54 (s, 1H), 7.95 (d, J = 7.7 Hz, 2H), 7.73-7.69 
(m, 2H), 7.63 (t, J = 7.3 Hz, 1H), 4.45 (tt, J = 11.7 Hz, J = 4.0 Hz, 1H), 





NMR (100 MHz, DMSO-d6, 298 K): δ = 143.9, 140.5, 135.1, 130.5, 130.1, 120.7, 58.4, 
32.0, 24.4, 24.2. HRMS (ESI) calcd, [C14H18N3]
+




The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.36) yielded the 
product as a white solid in 70% yield (128 mg, 0.348 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 10.83 (s, 1H), 9.71 (s, 1H), 7.99 (d, J = 7.7 Hz, 2H), 7.73-7.69 
(m, 2H), 7.63 (t, J = 7.3 Hz, 1H), 2.26 (bs, 9H), 7.99 (d, J = 7.7 Hz, 2H), 7.99 (d, J = 7.7 




H} NMR (100 MHz, 
DMSO-d6, 298 K): δ = 142.6, 139.7, 135.2, 130.4, 130.1, 120.8, 60.6, 41.4, 34.9, 28.8. 
HRMS (ESI) calcd, [C18H22N3]
+
 280.1808; observed, 280.1797.  
 
1,4-Diphenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2d]BF4). 
 The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.22) yielded the 
product as an off-white solid in 96% yield (148 mg, 0.479 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.43 (s, 1H), 10.01 (s, 1H), 8.04 (d, J = 7.7 Hz, 2H), 7.94 (d, J = 
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H} NMR (100 MHz, DMSO-d6, 
298 K): δ = 143.3, 140.5, 134.9, 132.1, 130.8, 130.3, 122.6, 120.8. HRMS (ESI) calcd, 
[C14H12N3]
+




1,4-Diphenyl-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate ([2d]OTf). 
 The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.17) yielded the 
product as a white solid in 95% yield (176 mg, 0.473 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.43 (s, 1H), 10.01 (s, 1H), 8.04 (d, J = 7.7 Hz, 2H), 7.94 (d, J = 




H} NMR (100 MHz, DMSO-d6, 
298 K): δ = 143.3, 140.5, 134.9, 132.1, 130.8, 130.3, 122.6, 120.7. HRMS (ESI) calcd, 
[C14H12N3]
+




The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.56) yielded the 
product as an off-white solid in 96% yield (189 mg, 0.480 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.38 (s, 1H), 9.93 (s, 1H), 8.05 (d, J = 7.7 Hz, 2H), 7.78-7.67 
(m, 4H), 7.54 (d, J = 7.7 Hz, 2H), 2.57 (sept, J = 6.7 Hz,12H’), 1.19 (d, J = 6.7 Hz, 6H’) 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 146.0, 145.5, 
142.1, 135.1, 132.4, 130.8, 130.0, 127.2, 124.8, 120.9, 27.7, 24.2, 23.5. HRMS (ESI) 
calcd, [C20H24N3]
+





tetrafluoroborate ([2f]BF4).  
The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.35) yielded the 
product as an off-white solid in 79% yield (181 mg, 0.394 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.13 (s, 1H), 9.73 (s, 1H), 7.97 (d, J = 7.7 Hz, 2H), 7.89 (dd, J = 
7.9 Hz, J = 1.4 Hz, 1H), 7.79-7.64 (m, 6H), 7.06 (d, J = 8.6 Hz, 2H), 6.76 (d, J = 8.6 Hz, 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 158.5, 
145.5, 141.8, 134.7, 133.8, 132.2, 132.1, 132.0, 130.9, 130.3, 129.9, 128.9, 128.3, 127.2, 
120.6, 113.9, 54.9, 38.4. HRMS (ESI) calcd, [C22H20N3OS]
+
 374.1322; observed, 
274.1305.  
 
4-(2-Fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2g]BF4).  
The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.17) yielded the 
product as an off-white solid in 95% yield (155 mg, 0473 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.47 (s, 1H), 10.03 (s, 1H), 8.03 (d, J = 7.7 Hz, 2H), 7.97-7.93 
(m, 1H), 7.87-7.81 (m, 2H), 7.79-7.75 (m, 2H), 7.69 (t, J = 7.3 Hz, 1H) 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 162.2 (d, JC-F = 
245.1 Hz), 143.3, 140.7, 134.8, 133.2 (d, JC-F = 11.0 Hz), 132.4 (d, JC-F = 8.8 Hz), 130.9, 




H} NMR (376 MHz, DMSO-d6, 298 K, referenced to C6H5F): δ = -109.97, -148.42. 
HRMS (ESI) calcd, [C14H11FN3]
+




4-(3-Fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2h]BF4).  
The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.17) yielded the 
product as a pale-yellow solid in 96% yield (158 mg, 0.482 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.42 (s, 1H), 9.93 (d, J = 1.7 Hz, 1H), 8.03 (d, J = 7.7 Hz, 2H), 





H} NMR (100 MHz, DMSO-d6, 298 K): δ = 154.3 (d, JC-F = 252.7 Hz), 144.6 
(d, JC-F = 3.8 Hz), 142.0, 134.8, 133.3 (d, JC-F = 8.0 Hz), 130.9, 130.3, 126.7, 126.0 (d, JC-





(376 MHz, DMSO-d6, 298 K, referenced to C6H5F): δ = -123.16, -148.41. HRMS (ESI) 
calcd, [C14H11FN3]
+
 240.0932; observed, 240.0921.  
 
4-(4-Fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2i]BF4).  
The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.19) yielded the 
product as an off-white solid in 94% yield (154 mg, 0.470 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.42 (s, 1H), 9.96 (s, 1H), 8.04-7.98 (m, 4H), 7.78-7.75 (m, 2H), 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 162.9 (d, JC-F = 
249.9 Hz), 143.5, 140.7, 134.9, 130.8, 130.4, 128.5 (d, JC-F = 2.9 Hz), 125.4 (d, JC-F = 9.6 




H} NMR (376 MHz, DMSO-d6, 298 K, 
referenced to C6H5F): δ = -109.92, -148.41. HRMS (ESI) calcd, [C14H11FN3]
+
 240.0932; 




4-(2-Chlorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2j]BF4).  
The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.19) yielded the 
product as an off-white solid in 95% yield (136 mg, 0.474 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.41 (s, 1H), 9.95 (s, 1H), 8.04 (d, J = 7.7 Hz, 2H), 7.97-7.92 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 153.9, 
145.2, 142.4, 134.8, 133.3, 131.0, 130.3, 129.4, 129.0, 128.7, 128.5, 120.9. HRMS (ESI) 
calcd, [C14H11ClN3]
+
 256.0636; observed, 256.0627. 
 
4-(4-Chlorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2k]BF4). 
 The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.37) yielded the 
product as an off-white solid in 90% yield (155 mg, 0.491 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.45 (s, 1H), 10.00 (s, 1H), 8.03 (d, J = 7.7 Hz, 2H), 7.98 (d, J = 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 143.3, 140.6, 135.4, 134.8, 131.0, 
130.9, 130.4, 130.3, 124.5, 120.7. HRMS (ESI) calcd, [C14H11ClN3]
+
 256.0636; 
observed, 256.0627.  
 
1-Phenyl-4-(pyridin-2-yl)-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2l]BF4). 
 The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.22) yielded the 
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product as a white solid in 82% yield (127 mg, 0.410 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.68 (s, 1H), 10.24 (s, 1H), 8.77-8.75 (m, 1H), 8.37-8.32 (m, 





H} NMR (100 MHz, DMSO-d6, 298 K): δ = 149.5, 144.7, 142.0, 140.9, 139.7, 
134.9, 130.9, 130.28, 126.2, 120.9, 115.4. HRMS (ESI) calcd, [C13H11N4]
+
 223.0978; 
observed, 223.0973.  
 
1-Phenyl-4-(pyrimidin-2-yl)-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2m]BF4). 
 The title compound was prepared according to general procedure IIb. After evaporation 
of the reaction solvent, the crude residue was washed with diethyl ether (5 mL), THF (3 
X 5 mL), acetone (3 times 2 mL). Recrystallization from methanol yielded the pure 
product as pale yellow solid in 58% yield (89.9 mg, 0.288 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.83 (s, 1H), 10.33 (s, 1H), 9.19 (d, J = 4.9 Hz, 2H), 8.14 (d, J = 




H} NMR (100 MHz, 
DMSO-d6, 298 K): δ = 160.4, 151.0, 142.2, 140.1, 134.8, 131.0, 130.2, 123.4, 121.2. 
HRMS (ESI) calcd, [C12H10N5]
+




4-Phenyl-1-(o-tolyl)-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate ([3d]OTf). 
 The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.17) yielded the 
product as an off-white solid in 81% yield (155 mg, 0.404 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.17 (s, 1H), 10.03 (s, 1H), 7.94 (d, J = 7.7 Hz, 2H), 7.79-7.53 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 143.0, 142.8, 
134.1, 133.8, 132.1, 132.0, 131.6, 130.7, 130.2, 127.3, 126.3, 122.6, 17.3. HRMS (ESI) 
calcd, [C15H14N3]
+




 The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.24) yielded the 
product as a white solid in 67% yield (140 mg, 0.333 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.2 (s, 1H), 9.97 (s, 1H), 7.79 (dd, J = 7.5 Hz, J = 2.2 Hz, 1H), 





H} NMR (100 MHz, DMSO-d6, 298 K): δ = 175.4, 164.8, 158.8, 156.3, 146.9, 
144.2, 140.4, 131.5, 130.1, 127.0, 125.3, 122.9, 121.0, 38.3, 26.3. HRMS (ESI) calcd, 
[C15H13ClN3]
+




4-Benzyl-1-mesityl-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate ([4a]OTf). 
 The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.18) yielded the 
product as an off-white solid in 58% yield (123 mg, 0.287 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 10.60 (s, 1H), 9.59 (s, 1H), 7.53-7.45 (m, 5H), 7.16 (s, 2H), 5.63 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 
146.2, 145.4, 141.9, 135.1, 133.9, 131.6, 129.9, 129.7, 129.6, 129.1, 51.6, 21.1, 17.3. 
HRMS (ESI) calcd, [C18H20N3]
+
 278.1652; observed, 278.1642.  
 
4-Cyclohexyl-1-mesityl-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate ([4b]OTf).  
The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.54) yielded the 
product as an off-white solid in 86% yield (181 mg, 0.431 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 10.55 (s, 1H), 9.56 (s, 1H), 7.17 (s, 2H), 4.48 (tt, J = 11.5 Hz, J = 
3.8 Hz, 1H), 2.35 (s, 3H), 2.32-2.28 (m, 2H), 2.04 (s, 6H), 1.91-1.68 (m, 5H), 1.50-1.38 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 144.4, 
143.5, 141.4, 134.8, 132.2, 129.4, 58.4, 31.8, 24.3, 24.2, 20.7, 16.8. HRMS (ESI) calcd, 
[C17H24N3]
+





trifluoromethanesulfonate ([4c]OTf).  
On a 0.5 mmol scale, The title compound was prepared according to general procedure 
IIb Purification by column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 
0.56) yielded the product as an off-white solid in 75% yield (176 mg, 0.374 mmol). 
Purification of 8 mmol scale: After evaporation of the reaction solvent, the crude product 
was dissolved in DCM (50 mL), filtered and crashed out with hexanes (70 mL) which 
yielded the pure product as a colorless powder in 77% yield (2.89 g, 6.13 mmol). 
1
H 
NMR (400 MHz, DMSO-d6, 298 K): δ = 10.65 (s, 1H), 9.81 (s, 1H), 7.18 (s, 1H), 2.35 (s, 




H} NMR (100 MHz, DMSO-d6, 
298 K): δ = 143.3, 142.7, 141.4, 134.8, 131.3, 129.4, 60.9, 41.3, 34.7, 28.9, 20.7, 16.9. 
HRMS (ESI) calcd, [C21H28N3]
+
 322.2278; observed, 322.2273.  
 
1-Mesityl-4-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([4d]BF4). 
The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.36) yielded the 
product as an off-white solid in 52% yield (91 mg, 0.266 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.10 (s, 1H), 10.11 (s, 1H), 7.97 (d, J = 8.0 Hz, 2H), 7.78-7.74 





(100 MHz, DMSO-d6, 298 K): δ = 143.8, 143.2, 141.6, 134.9, 132.2, 131.0, 130.7, 130.2, 
129.5, 122.5, 20.7, 17.0. HRMS (ESI) calcd, [C17H18N3]
+
 264.1495; observed, 264.1490.  
 
1-Mesityl-4-phenyl-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate ([4d]OTf).  
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The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.19) yielded the 
product as an off-white powder in 74% yield (153 mg, 0.372 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.10 (s, 1H), 10.11 (s, 1H), 7.96 (d, J = 8.0 Hz, 2H), 7.78-7.74 





(100 MHz, DMSO-d6, 298 K): δ = 143.8, 143.2, 141.6, 134.9, 132.2, 131.0, 130.6, 130.1, 
129.5, 122.5, 20.7, 17.0. HRMS (ESI) calcd, [C17H18N3]
+ 
264.1495; observed, 264.1485.  
 
1-Mesityl-4-(2-((4-methoxybenzyl)thio)phenyl)-4H-1,2,4-triazol-1-ium 
trifluoromethanesulfonate ([4f]OTf).  
The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.48) yielded the 
product as a light brown oil (which solidified upon standing) in 59% yield (166 mg, 
0.229 mmol). 
1
H NMR (400 MHz, DMSO-d6, 298 K): δ = 10.95 (s, 1H), 9.68 (s, 1H), 
7.91 (dd, J = 7.9 Hz, J = 1.3 Hz, 1H), 7.88 (dd, J = 7.9 Hz, J = 1.3 Hz, 1H), 7.74 (td, J = 
7.7 Hz, J = 1.3 Hz, 1H), 7.66 (td, J = 7.7 Hz, J = 1.3 Hz, 1H), 7.22 (s, 2H), 7.10 (d, J = 
8.7 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 4.20 (s, 2H), 3.72 (s, 3H), 2.37 (s, 3H’), 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 158.6, 146.0, 145.6, 
141.7, 134.8, 133.1, 132.7, 132.2, 131.8, 130.8, 129.9, 129.5, 128.5, 128.2, 127.7, 55.1, 
38.3, 20.7, 17.0. HRMS (ESI) calcd, [C25H26N3OS]
+






 The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.47) yielded the 
product as a white powder in 54% yield (117 mg, 0.277 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.05 (s, 1H), 10.06 (s, 1H), 8.04-8.01 (m, 2H), 7.68-7.63 (m, 




H} NMR (100 MHz, DMSO-d6, 298 
K): δ = 162.7 (d, JC-F = 248.6 Hz), 144.0, 143.3, 141.6, 134.9, 131.0, 129.5, 




H} NMR (376 MHz, DMSO-d6, 298 K, referenced to C6H5F): δ = -77.85, -110.18. 
HRMS (ESI) calcd, [C17H17FN3]
+




 The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.43) yielded the 
product as an off-white powder in 58% yield (130 mg, 0.291 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.10 (s, 1H), 10.10 (s, 1H), 8.00 (d, J = 8.9 Hz, 2H), 7.88 (d, J = 




H} NMR (100 MHz, 
DMSO-d6, 298 K): δ = 143.9, 143.3, 241.6, 135.2, 134.9, 131.2, 131.0, 130.1, 129.5, 
124.5, 20.7, 17.0. HRMS (ESI) calcd, [C17H17ClN3]
+






 The title compound was prepared according to general procedure IIb. Purification by 
washing with hexanes (2 times, 10 mL) and diethyl ether (2 times, 10 mL, followed by 
recrystallization from 1,4-dioxane, yielded the product as a colorless powder in 54% 
yield (112 mg, 0.271 mmol). 
1
H NMR (400 MHz, DMSO-d6, 298 K): δ = 11.37 (s, 1H), 
10.30 (s, 1H), 8.74-8.73 (m, 1H), 8.34-8.30 (m, 1H), 8.12 (d, J = 8.2 Hz, 1H), 7.77-7.74 




H} NMR (100 MHz, DMSO-d6, 
298 K): δ = 149.3, 145.0, 142.8, 142.6, 141.6, 140.6, 134.9, 131.1, 129.4, 126.0, 115.5, 
20.7, 17.0. HRMS (ESI) calcd, [C16H17N4]
+




The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.41) yielded the 
product as an off-white powder in 96% yield (175 mg, 0.478 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 10.78 (s, 1H), 9.69 (s, 1H), 8.32 (d, J = 8.3 Hz, 1H), 8.20-8.18 
(m, 1H), 7.97-7.95 (m, 1H), 7.86-7.69 (m, 4H), 4.52 (tt, J = 11.6 Hz, J = 3.9 Hz, 1H), 





NMR (100 MHz, DMSO-d6, 298 K): δ = 144.0, 143.7, 133.7, 132.0, 131.2, 128.5, 128.3, 
127.6, 127.1, 125.3, 125.1, 122.1, 58.4, 31.9, 24.4, 24.2. HRMS (ESI) calcd, [C18H14N3]
+
 
278.1652; observed, 278.1647.  
 
1-(Naphthalen-1-yl)-4-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([5d]BF4).  
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The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.19) yielded the 
product as a brown powder in 81% yield (145 mg, 0.406 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.36 (s, 1H), 10.15 (s, 1H), 8.37 (d, J = 8.4 Hz, 1H), 8.24-8.20 





(100 MHz, DMSO-d6, 298 K): δ = 143.7, 143.4, 133.7, 132.2 (2 signals), 131.0, 130.7, 
130.3, 128.5, 128.4, 127.7, 127.1, 125.4, 125.2, 122.6, 122.3. HRMS (ESI) calcd, 
[C18H14N3]
+
 272.1182; observed, 272.1173.  
 
1-(4-Methoxyphenyl)-4-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([6d]BF4). 
 The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.19) yielded the 
product as a pale brown powder in 91% yield (155 mg, 0.456 mmol). 
1
H NMR (400 
MHz, DMSO-d6, 298 K): δ = 11.30 (s, 1H), 9.97 (s, 1H), 7.96-7.91 (m, 4H), 7.86-7.74 





(100 MHz, DMSO-d6, 298 K): δ = 160.7, 143.1, 139.7, 132.1, 130.7, 130.3, 128.0, 122.5, 
115.28, 55.8. HRMS (ESI) calcd, [C15H14N3O]
+




The title compound was prepared according to general procedure IIb on a 3 mmol scale. 
After evaporation of the reaction solvent, the crude product was washed with hexanes 
(2 times, 10 ml), diethyl ether (2 times, 10 mL), and THF (3 times, 5 mL). Extraction of 
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the resulting solid with acetone (2 times 10 mL) yielded the desired product upon 
evaporation as a pale brown powder in 53% yield (273 mg, 0.798 mmol). 
1
H NMR (400 
MHz, DMSO-d6, 298 K): δ = 11.69 (s, 1H), 10.27 (s, 1H), 9.16 (d, J = 4.5 Hz, 2H), 8.04 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 160.9, 160.4, 151.0, 142.1, 139.2, 
127.8, 123.3, 122.9, 115.2, 55.9. HRMS (ESI) calcd, [C15H14N3O]
+





The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.37) yielded the 
product as an off-white solid in 95% yield (178 mg, 0.473 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.59 (s, 1H), 10.08 (s, 1H), 8.45 (s, 1H), 8.37 (d, J = 8.0 Hz, 
1H), 8.10 (d, J = 8.0 Hz, 1H), 8.03 (t, J = 8.0 Hz, 1H), 7.94 (d, J = 7.7 Hz, 2H), 7.81-




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 
143.2, 142.3, 135.3, 131.8, 130.6, 130.5 (q, J = 32.8 Hz), 130.2, 127.2 (q, J = 3.8 Hz), 




H} NMR (376 MHz, 
DMSO-d6, 298 K, referenced to C6H5F): δ = -61.42, -148.42. HRMS (ESI) calcd, 
[C15H14N3O]
+
 290.0900; observed, 290.0891.  
 
4-(2,6-Diisopropylphenyl)-1-(3-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-1-ium 
tetrafluoroborate ([7e]BF4).  
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The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.50) yielded the 
product as a pale yellow-green oil in 98% yield (226 mg, 0.489 mmol). 
1
H NMR (400 
MHz, DMSO-d6, 298 K): δ = 11.48 (s, 1H), 9.98 (s, 1H), 8.43 (s, 1H), 8.39 (d, J = 8.0 
Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 8.02 (t, J = 8.0 Hz, 1H), 7.73 (t, J = 7.8 Hz, 1H), 7.55 
(d, J = 7.8 Hz, 2H), 2.60 (sept, J = 6.7 Hz, 2H), 1.20 (d, J = 6.7 Hz, 6H), 




H} NMR (100 MHz, DMSO-d6, 298 K): δ = 146.0, 145.5, 
143.1, 135.8, 132.5, 131.5, 130.4 (q, J = 32.9 Hz), 127.2 (q, J = 3.7 Hz), 127.1, 125.1, 




H} NMR (376 MHz, DMSO-
d6, 298 K, referenced to C6H5F): δ = -61.37, -148.41. HRMS (ESI) calcd, [C15H14N3O]
+
 




The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.11) yielded the 
product as off-white powder in 74% yield (144 mg, 0.369 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.41 (s, 1H), 10.02 (s, 1H), 8.11-8.06 (m, 2H), 7.94 -7.92 (m, 





H} NMR (100 MHz, DMSO-d6, 298 K): δ = 162.8 (d, J = 247.9 Hz), 143.3, 
140.7, 132.0, 131.4 (d, J = 3.0 Hz), 130.8, 130.3, 123.5 (d, J = 9.3 Hz), 122.5, 




H} NMR (376 MHz, DMSO-d6, 298 K, referenced to 
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C6H5F): δ = -77.85, -109.86. HRMS (ESI) calcd, [C15H14N3O]
+




trifluoromethanesulfonate ([8e]OTf).  
The title compound was prepared according to general procedure IIb. Purification by 
column chromatography (silica, 1. DCM, 2. DCM/acetone 4:1, Rf = 0.44) yielded the 
product as an off-white solid in 91% yield (216 mg, 0.456 mmol). 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.34 (s, 1H), 9.93 (s, 1H), 8.13-8.10 (m, 2H), 7.72 (t, J = 7.8 Hz, 
1H), 7.66-7.62 (m, 2H), 7.55 (t, J = 7.8 Hz, 2H), 2.58 (sept, J = 6.7 Hz, 2H), 1.20 (d, J = 




H} NMR (100 MHz, DMSO-d6, 298 K): 
δ = 162.8 (d, J = 248.9 Hz), 146.0, 145.5, 142,2, 132.4, 131.7 (d, J = 3.0 Hz), 127.1, 




H} NMR (376 
MHz, DMSO-d6, 298 K, referenced to C6H5F): δ = -77.85, -109.94. HRMS (ESI) calcd, 
[C15H14N3O]
+






IODINE MEDIATED C–H ACTIVATION LEADING TO BENZO[4,5]IMIDAZO- 
[2,1-c][1,2,4]TRIAZOL-1-IUM SALTS 
 
Section 3.0: Introduction 
Fused bicyclic azoles containing 1,2,4-triazole and imidazole units have shown  








 Fused bicyclic azoles containing a 1,2,4-triazole 
unit are primarily synthesized via two methods. One method employs substituted 
hydrazonyl halides which are coupled with thioether substituted azoles by two sequential 
nucleophilic acyl substitutions. (Schemes 11-13).
76,78,137–145
 Alternatively, amino or 
hydrazinyl azoles are used as the structural template to synthesize 1,2,4-triazole-
containing bicyclic azoles (Schemes 14-18).
2,39,80,146
 Both of these approaches employ 
complex starting materials in a convergent synthesis to access highly functionalized 
imidazo[1,2-a]imidazoles. More recent methods involve C(sp
2
)-H activation, allowing for 
post functionalization of a preexisting azole in the presence of an amine nucleophile.
147–
150
 The Roy group previously explored the C(sp
2
)-H activation of imidazolium, 
thiazolium, and a few triazolium salts using I2 as the oxidant under basic conditions. 
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Roy and coworkers showed that the C(sp
2
)-H activation results in imination and 
amination of the C
2
 position in the presence of an amine nucleophile with yields ranging 
from 66-91% (Scheme 21a).
150
 The Fu group synthesized 9H-benzo[d]imidazo[1,2-
a]imidazole using Cu(I) catalysis in the presence of oxygen at high temperatures to carry 
out the C(sp
2
)-H activation and subsequent intramolecular cyclization of ortho-
substituted secondary anilines to form a guanidine moiety in 82-97% yields (Scheme 
21b).
147
 Similar Cu(I) catalyzed C(sp
2





 employing different amine sources and a multi-step one-pot synthesis, 
respectively, to obtain imidazo[1,2-a]imidazole and imidazo[2,1-c][1,2,4]-triazoles. We 
developed an alternative method for the synthesis of 9H-benzo[4,5]imidazo[2,1-c][1,2,4]-
triazol-1-ium salts employing iodine-promoted C(sp
2
)-H activation, leading to an 
intramolecular amination of 4-(2-ammoniophenyl)-1-substituted-4H-1,2,4-triazol-1-ium 
chlorides (Scheme 21c).  
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Scheme 21. Previous Research on the C–H Activation of Azoles 
 
 
Section 3.1 Initial Formation of Benzo[4,5]imidazo[2,1-c][1,2,4}triazol-1-ium Salts  
Initially, we detected an unexpected byproduct 12x during the synthesis of 4-(2-
aminophenyl)-1-substituted-4H-1,2,4-triazol-1-ium salts 11x during iron-catalyzed 
reduction of 1-substituted-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium salts 10x (Scheme 
22).  




Attempts to optimize this method for the synthesis of 9H-benzo[4,5]imidazo[2,1-
c][1,2,4]triazol-1-ium chlorides under iron-promoted reductive conditions failed. We 
were unable to discover conditions that exclusively formed the cyclized product for both 
aryl and alkyl substituents. Testing optimized methods on phenyl and benzyl-containing 
substrates, we discovered that the phenyl substrate more readily cyclized, while the 
benzyl substrate failed to undergo the cyclization. After 4 h, complete conversion was 
obtained for all substrates. Allowing the reaction to continue for 20 h resulted in no 
appreciable increase in the formation of the respective cyclized products. We discovered 
methods that formed the amine product exclusively during this optimization, which was 
used to form the precursors for the final step. Searching the literature for proposed 
mechanisms of the iron-catalyzed reduction of an aromatic nitro, we hypothesized that 
the nitroso or hydroxylamine intermediates thought to form during the reduction were 
essential for this cyclization. Since the reduction failed, we attempted to obtain the 
heterocycle 12x under oxidative conditions from 4-(2-aminophenyl)-1-substituted-4H-
1,2,4-triazol-1-ium salts. 
Section 3.2: Synthesis of Starting Material for the Iodine-Promoted Intramolecular 
Cyclization 
We began by synthesizing 1-substituted-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium salts 
(10n-10w), starting from 4-(2-nitrophenyl)-4H-1,2,4-triazole. We arylated 4-(2-
nitrophenyl)-4H-1,2,4-triazole using our copper-catalyzed N-arylation method to acquire 
substrates 10q-10u in high yields (82-94%). We also alkylated 4-(2-nitrophenyl)-4H-
1,2,4-triazole in high yields (80-91%), introducing the alkyl substituents benzyl (10n), 
isopropyl (10o), allyl (10v), 2-methylallyl (10w), and 3-butynyl (10p) (Table 7).  
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Table 7. Synthesis of 1-Substituted-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium Salts 
 
a) Reaction conditions: 4-(2-nitrophenyl)-4H-1,2,4-triazole (1.0 equiv), diaryl iodonium salt 
(1.5 equiv), Cu(I)OAc, MeCN, 80 °C, 20 h. 
b)
 Reaction conditions: 4-(2-nitrophenyl)-4H-
1,2,4-triazole (1.0 equiv), alkyl bromide (1.0-4.0 equiv), MeCN, 80 °C, 20 h. 
 
One problem encountered while converting the 1-substituted-4-(2-nitrophenyl)-4H-1,2,4-
triazol-1-ium salts (10n-10w) to the amine using iron as the reducing agent under acidic 
conditions, was that the free base form of 4-(2-aminophenyl)-1-substituted-4H-1,2,4-
triazol-1-ium salts rapidly decomposed. Therefore we isolated all of these compounds as 




Table 8. Synthesis of 4-(2-Ammoniophenyl)-1-substituted-4H-1,2,4-triazol-1-ium 
Chlorides a 
 
a) Reaction conditions: 1) 4-nitrophenyl-1,2,4-triazolium salt (1.0 equiv), NH4Cl (10 equiv) 
Fe(0) (10 equiv), EtOH/H2O 9/1, 50 °C, 4 h. 2) 4 equiv of HCl (4 M in dioxanes) 
Section 3.3: Optimization of Iodine-Promoted Intramolecular Cyclization 
To optimize the cyclization reaction under oxidative conditions, we charged a microwave 
vial with 11n and the chosen oxidant and tested different reaction conditions shown in 
Table 9. We subjected 11n to different oxidants, such as m-CPBA, H2O2, DMSO, and 
DMSO/ I2. Among the oxidants attempted, only DMSO/I2 resulted in conversion of the 
69 
 
starting material to the product.  All other oxidants failed to give 12n, either reforming 
the 1-substituted-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium salts 11n (H2O2), decomposing 
the starting material (m-CPBA), or achieved incomplete conversion (DMSO anhy). We 
refined the reaction using iodine as the oxidant in DMSO and an excess of the base 
(Table 9). Initially, we screened six different bases; NaHCO3 (1.1 equiv), K2CO3 (1.1 
equiv), NEt3 (4.0 equiv), t-BuOK (4.0 equiv), imidazole (4.0 equiv), DBU (4.0 equiv), 
and with no base in DMSO at room temperature (Table 9, Entries 1-7). We found that t-
BuOK and DBU were the best bases with DMSO solvent. It was decided that DBU was 
an easier base with which to work and provided slightly higher yields. Given the yields 
with the basic salts NaHCO3 and K2CO3, no repetition of the reaction with 4 equiv of base 
was performed. We then varied the ratio of base to oxidant and found that an excess of 
DBU to I2 yielded the best results (Table 9, Entries 8-9). Testing the solvents MECN, 
EtOH, EtOAc, and DCM and allowing overnight reaction, it was found that DCM and 
MECN achieved similar but slightly lower yields compared to the DMSO reactions 
(Table 9. Entries 10-13). We decided that using DCM and MECN would result in easier 
purification via column chromatography. To validate this hypothesis, we obtained 
isolated yields from reaction in DCM, MECN, and DMSO, confirming that DCM 
provided greater ease of purification resulting in higher isolated yields.  
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6 0.1 Imidazole (4)
a









































Reaction conditions: triazolium salt 11n (0.1 mmol), Base, Oxidant: I2 (2eq), solvent (5 
mL, 0.02M), and reaction time. 
b) 
Relative to 11n. 
c) 
Conversion based on LCMS analysis.  
 
Section 3.4: Substrate Scope for the Iodine-Promoted Intramolecular Cyclization 
The substrate scope was tested by subjecting our substrates to our optimized reaction 
conditions. We found that the cyclization was higher yielding with aliphatic substituents 
(12n: 46%, 12o: 63%), also allowing for alkyne (12p: 52%) and alkenes (12v: 42%, 12w: 
34%). Aryl substituents are also tolerated but progressed with lower yield; electron-rich 
and weakly electron-withdrawing aryl substrates displayed similar yields (12r: 39%, 
12s: 23%, 12t: 32%), with the para-chlorophenyl and unsubstituted phenyl having 
noticeably lower yields (12q: 19%, 12u: 12%). Strongly electron-withdrawing groups 




Table 10. Substrate Scope for the Iodine-Promoted Intramolecular Cyclization 
Table 10. Reaction conditions: 4-(2-ammoniophenyl)-[1,2,4]-triazol-1-ium chlorides 
(1.0 equiv)  I2 (2.0 equiv), DBU (4.0 equiv), DCM (0.02 M), 37 °C, 4 hours 
 
Section 3.5: Potential Mechanism for the Iodine-Promoted Intramolecular 
Cyclization  
The Roy group previously theorized that their iodine-promoted imination progressed 
through an iodoimidazolium intermediate (Scheme 23a). They observed, isolated, and 
characterized the iodoimidazolium salt, and when subjecting the iodoimidazolium salt to 
their optimized reaction conditions obtained near quantitative yields (Scheme 23a).
150
 
Likewise, we have observed the formation of a similar iodotriazolium intermediate by 
LCMS (Scheme 23b). Upon addition of iodine, the triazolium salt was observed to be 
converted to the iodotriazolium amines via LCMS, indicating complete conversion after 1 
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hour. Conducting the reaction in hygroscopic solvents, we observed the formation of the 
oxo-triazole species. The Roy Group also studied the formation of the oxo-imidazole 
when water was used as the nucleophile.
150
 We observed that ion pairing was still present 
in the product. We hypothesized that the second deprotonation proposed by the Roy 
group for their imidazolium salts did not occur in the case of 1,2,4 triazolium salts.  
Scheme 23. Plausible Mechanism for Iodine-Promoted Intramolecular Cyclization 
 
Scheme 23. a) Mechanism proposed by the Roy group. b) Similar mechanism proposed 
by the Bolliger group.  
 
Section 3.6: Conclusion 
In this work, we have developed an alternative synthesis of 9H-benzo[4,5]imidazo[2,1-
c][1,2,4]triazol-1-ium salts under relatively mild conditions utilizing inexpensive starting 
materials. Despite yields being lower than desired, we believe that the substrate specific 
optimization could significantly increase yields for particular substrates. This research 
revealed a new synthetic pathway for fused 1,2,4-triazole containing bicyclic azoles, 
which could potential allow for the development of novel drug molecules. 
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Section 3.7: Procedure and Characterization data for 4-(2-Nitrophenyl)-
[1,2,4]triazole 
Synthesis of 4-(2-Nitrophenyl)-[1,2,4]triazole (SMI) (General Procedure III) 
A mortar was loaded with 2-nitroaniline (1 equiv), N,N-dimethylformylamide azine 
(DMAZ, 1.5 equiv), and para-toluenesulfonic acid (TsOH, 0.05 equiv). This mixture was 
ground together until the mixture became a homogeneous solid. The mixture was then 
transferred to a round-bottomed flask equipped with a stir bar which was then fitted with 
a reflux condenser. The mixture was heated (neat) to 150 °C for 16 hours with constant 
stirring. 
Workup: After 16 hours, the mixture was cooled to 23 °C and completely dissolved using 
1 M NaOH (aq), and the mixture was then extracted with DCM (3 x 100 mL). The 
organic layer was washed with H2O (2 x 50 mL), dried (MgSO4), filtered, and 
concentrated on a vacuum rotary evaporator. The crude product was purified by 
precipitating from DCM (~20 mL) using excess diethyl ether. Alternatively, purification 
was carried out by column chromatography eluted with DCM/methanol (95:5) or 
DCM/acetone (7:3) if precipitation resulted in an impure mixture.  
Observations: The reaction mixture liquefied during heating, and efficient stirring did not 







The title compound was prepared on a 98 mmol scale according to the general procedure 
III. Purification by DCM-ether precipitation yielded the product as brown-orange powder 
in 51% yield (9.48 g, 49.9 mmol). Purification by column chromatography (silica, 
DCM/acetone 7:3, Rf = 0.22) also resulted in a pure product. 
1
H NMR (400 MHz, CDCl3, 
298 K): δ = 8.30 (s, 2H), 8.13 (dd, J = 8.1 Hz, J = 1.3 Hz, 1H), 7.81 (td, J = 7.7 Hz, J 





H} NMR (101 MHz, CDCL3, 298 K): δ = 144.8, 142.9, 134.7, 131.3, 129.3, 
127.1, 126.1. NMR Data is in accordance with literature.
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 HRMS (ESI) calcd, 
[C8H6N4O2]H
+
 191.0564; observed, 191.0559. 
 
Section 3.8: General Procedure and Characterization Data for 1-Substituted-4-(2-
nitrophenyl)-4H-1,2,4-triazol-1-ium Salts 
Catalytic Arylation of 4-(2-Nitrophenyl)-4H-1,2,4-triazole (sm1) General Procedure 
IV 
4-(2-Nitrophenyl)-4H-1,2,4-triazole (1.0 equiv), diaryliodonium salt (1.0-1.1 equiv), 
copper(I) acetate (0.05 equiv), was also added to a round-bottomed flask and dissolved in 
acetonitrile (0.25 M). The flask was fitte with a reflux condenser, and the atmosphere was 
exchanged for argon. The solution was heated to reflux (82 °C) for 16 h with constant 
stirring.  
Workup: The solvent was removed under vacuum, and the product was dissolved in a 
minimum amount of 9:1 DCM/acetone. This mixture was then stirred with slow addition 
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of diethyl ether until no more solid precipitated out. If further purification was needed, a 
silica column eluted with a DCM/acetone gradient (8:2 then 7:3) results in a pure 
product.  
Observations: Overnight reaction times were necessary for the nitro-containing systems 
due to the deactivating effects of the nitro. Precipitation of product utilizing diethyl ether 
removed only small proportions of the 4-(2-nitrophenyl)-4H-1,2,4-triazole starting 
material. Column chromatography was required if considerable amounts of residual 
starting material were present.  
 
Alkylation of 4-(2-Nitrophenyl)-4H-1,2,4-triazole (sm1) General Procedure V 
4-(2-Nitrophenyl)-4H-1,2,4-triazole (1.0 equiv) and an alkyl bromide (equivalents varied) 
were loaded in a round-bottomed flask. Acetonitrile (2 M) was added and the flask was 
fitted with a reflux condenser, and heated to reflux (82 °C) with constant stirring 
overnight (16 h).  
Workup: The product was concentrated under vacuum. The product was loaded onto a 
silica column using DCM and eluted initially with DCM/methanol (8:2). An alternative 
purification method involved precipitating the product from DCM by dropwise addition 
of diethyl ether. 
Observations: Complete conversion of the 4-(2-nitrophenyl)-4H-1,2,4-triazole starting 





1-Benzyl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide (10n) 
The title compound was prepared on a 10 mmol scale according to general procedure V 
using 1.1 equiv of benzyl bromide. Purification by precipitation from DCM using diethyl 
ether followed by column chromatography (silica, DCM/methanol 8:2, Rf = 0.42), 
yielded the product as a light yellow powder in 88% yield (3.19 g, 8.8 mmol). 1H NMR 
(400 MHz, DMSO-d6, 298 K): δ = 10.80 (s, 1H), 9.64 (s, 1H), 8.49 (dd, J = 8.2 Hz, J = 1.3 Hz, 
1H), 8.13 (td, J = 8.0 Hz, J = 1.3 Hz, 1H), 8.09 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H), 8.02 (td, J = 8.3 




H} NMR (101 MHz, DMSO-d6, 298 K): δ =145.8, 144.0, 143.2, 135.7, 133.13, 132.9, 




1-Isopropyl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide (10o) 
The title compound was prepared on a 5 mmol scale according to general procedure V 
using 4 equiv of 2-bromopropane. Purification by precipitation from DCM using diethyl 
ether followed by column chromatography (silica, DCM/methanol 8:2, Rf = 0.30), 
yielded the product as a light yellow powder in 80% yield (1.26 g, 4.0 mmol). 
1
H NMR 
(400 MHz, DMSO-d6, 298 K): δ = 10.75 (s, 1H), 9.65 (s, 1H), 8.50 (dd, J = 8.2 Hz, J = 
1.3 Hz, 1H), 8.14 (td, J = 7.9 Hz, J = 1.3 Hz, 1H), 8.09 (dd,
 
J = 7.9 Hz, J = 1.9 Hz, 1H), 
8.02 (td,
 





H} NMR (101 MHz, DMSO-d6, 298 K): δ = 145.3, 143.2, 142.6, 135.7, 133.1, 
130.4, 126.5, 125.2, 55.8, 21.2. HRMS (ESI) calcd, [C11H13N4O2]
+




1-(But-3-yn-1-yl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide (10p) 
The title compound was prepared on a 5 mmol scale according to general procedure V 
using 1.5 equiv of 4-bromobut-1-yne. Purification by precipitation from DCM using 
diethyl ether followed by column chromatography (silica, DCM/methanol 8:2, Rf = 0.33), 
yielded the product as a light yellow powder in 81% yield (1.31 g, 4.1 mmol). 
1
H NMR 
(400 MHz, DMSO-d6, 298 K): δ = 10.80 (s, 1H), 9.69 (s, 1H), 8.50 (dd, J = 8.2 Hz, 
J = 1.4 Hz, 1H), 8.13 (td, J = 7.8 Hz, J =  1.4 Hz, 1H), 8.08-7.99 (dd,
 
J = 8.0 Hz, 
J = 1.5 Hz), (td,
 
J = 7.7 Hz, J =  1.5 Hz) 2H), 4.70 (t,
 
J = 6.6 Hz, 2H), 3.06 (t, J = 




H} NMR (101 MHz, DMSO-d6, 
298 K): δ = 145.5, 144.1, 143.2, 135.8, 133.2, 130.3, 126.6, 125.2, 79.1, 74.4, 50.6, 18.4. 
HRMS (ESI) calcd, [C12H11N4O2]
+
 243.0877; observed, 243.0870. 
4-(2-Nitrophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate (10q)  
The title compound was prepared on a 15.4 mmol scale according to general procedure 
IV using 1.5 equiv of diphenyliodonium trifluoromethanesulfonate. Purification by 
precipitation from DCM using diethyl ether followed by column chromatography (silica, 
DCM/acetone 7:3, Rf = 0.11), yielded the product as an off-white powder in 89% yield 
(5.70 g, 9.6 mmol). 
1
H NMR (400 MHz, DMSO-d6, 298 K): δ = 11.37 (s, 1H), 9.90 (s, 
1H), 8.54 (dd, J = 8.2 Hz, J = 1.3 Hz, 1H), 8.18 (td, J = 7.7 Hz, J = 1.3 Hz, 1H), 
8.13-8.04 (unresolved m, 2H), 8.02 (d, J = 7.6 Hz, 2H), 7.77 (t, J = 7.6 Hz, 2H), 




H} NMR (101 MHz, DMSO-d6, 298 K): δ =146.0, 143.2, 
142.8, 135.9, 134.6, 133.4, 131.0, 130.5, 130.3, 126.7, 125.0, 120.7. HRMS (ESI) calcd, 
[C14H11N4O2]
+
 267.0877; observed, 267.0870. 
78 
 
1-Mesityl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate (10r) 
The title compound was prepared on a 10 mmol scale according to general procedure IV 
using 1.2 equiv of dimesityliodonium trifluoromethanesulfonate. Purification by 
precipitation from DCM using diethyl ether followed by column chromatography (silica, 
DCM/acetone 7:3, Rf = 0.2), yielded the product as an off-white powder in 82% yield 
(3.78 g, 8.2 mmol). 
1
H NMR (400 MHz, DMSO-d6, 298 K): δ = 10.95 (s, 1H), 9.90 (s, 
1H), 8.56 (dd, J = 7.3 Hz, J = 1.3 Hz, 1H), 8.23 (dd, J = 7.9 Hz, J = 1.7 Hz, 1H), 
8.18 (td, J = 7.9 Hz, J = 1.3 Hz, 1H), 8.07 (td, J = 7.3 Hz, J = 1.7 Hz, 1H) 7.23 (s, 2H), 




H} NMR (101 MHz, DMSO-d6, 298 K): δ =146.3, 145.9, 
143.2, 141.8, 135.8, 134.8, 133.5, 130.8, 130.7, 129.5, 126.7, 125.1, 20.7, 16.9. HRMS 
(ESI) calcd, [C17H17N4O2]
+




The title compound was prepared on a 10 mmol scale according to general procedure IV 
using 1.01 equiv of bis(4-methoxyphenyl)iodonium tetrafluoroborate. Purification by 
precipitation from DCM using diethyl ether followed by column chromatography (silica, 
DCM/acetone 7:3, Rf = 0.17), yielded the product as a light brown powder in 94% yield 
(3.615 g, 9.4 mmol). 
1
H NMR (400 MHz, DMSO-d6, 298 K): δ = 11.24 (s, 1H), 9.85 (s, 
1H), 8.54 (dd, J = 8.2 Hz, J = 1.4 Hz, 1H), 8.18 (dd, J = 7.7 Hz, J = 1.4 Hz, 1H), 8.09 
(td, J = 7.7 Hz, J = 1.5 Hz, 1H), 8.06 (td, J = 8.2 Hz, J = 1.5 Hz, 1H), 7.94 (d, 




H} NMR (101 MHz, 
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DMSO-d6, 298 K): δ = 160.9, 145.8, 143.2, 142.0, 135.9, 133.4, 130.3, 127.6, 126.7, 







The title compound was prepared on a 5 mmol scale according to general procedure IV 
using 1.1 equiv of bis(4-fluorophenyl)iodonium trifluoromethanesulfonate. Purification 
by precipitation from DCM using diethyl ether followed by column chromatography 
(silica, DCM/acetone 7:3, Rf = 0.11), yielded the product as tan powder in 93% yield 
(2.02 g, 4.6 mmol). 
1
H NMR (400 MHz, DMSO-d6, 298 K): δ = 11.37 (s, 1H), 9.90 (s, 
1H), 8.54 (d, J = 8.0 Hz, 1H), 8.18 (td, J = 7.6 Hz, J = 1.3 Hz, 1H), 8.13-8.03 




H} NMR (101 MHz, DMSO-d6, 298 
K): δ = 163.3 (d, JC-F = 248.5 Hz), 146.4, 143.7, 136.4, 133.9, 131.5 (d, JC-F = 3.0 Hz), 
130.7, 127.2, 125.4, 123.9 (d, JC-F = 9.3 Hz), 117.9 (d, JC-F = 23.7 Hz); 
19
F NMR (376 







The title compound was prepared on a 5 mmol scale according to general procedure IV 
using 1.1 equiv of bis(4-chlorophenyl)iodonium trifluoromethanesulfonate. Purification 
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by precipitation from DCM using diethyl ether followed by column chromatography 
(silica, DCM/acetone 7:3, Rf = 0.11), yielded the product as an off-white powder in 92% 
yield (2.07 g, 4.6 mmol). 
1
H NMR (400 MHz, DMSO-d6, 298 K): δ = 11.40 (s, 1H), 9.91 
(s, 1H), 8.54 (d, J = 8.1 Hz, J = 1.3 Hz, 1H), 8.18 (t, J = 7.9 Hz, 1H), 8.10-8.02 




H} NMR (101 MHz, 
DMSO-d6, 298 K): δ = 146.0, 143.2, 143.2, 135.9, 135.8, 133.5, 133.4, 130.5, 130.3, 
126.8, 124.9, 122.6. HRMS (ESI) calcd, [C14H10ClN4O2]
+
 301.0487; observed, 301.0481. 
 
1-Allyl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide (10v) 
The title compound was prepared on a 5 mmol scale according to general procedure V 
using 1.1 equiv of allyl bromide. Purification by precipitation from DCM using diethyl 
ether followed by column chromatography (silica, DCM/methanol 4:1, Rf = 0.31), 
yielded the product as yellow powder in 87% yield (1.4 g, 4.4 mmol). 
1
H NMR (400 
MHz, DMSO-d6, 298 K): δ = 10.69 (s, 1H), 9.66 (s, 1H), 8.50 (dd, J = 8.2 Hz, 
J = 1.4 Hz, 1H), 8.13 (td, J = 7.7 Hz, J = 1.4 Hz, 1H), 8.07 (dd, J = 7.9, J = 1.6 Hz, 1H), 
8.02 (td, J = 7.7, J = 1.6 Hz, 1H), 6.14 (ddt, J = 16.5 Hz, J = 10.4 Hz, J = 6.0 Hz, 1H), 
5.51-5.43 ((dd, J = 10.4 Hz, J = 1.2 Hz), (dd, J = 16.5 Hz, J = 1.2 Hz), 2H), 5.24 (d, 




H} NMR (101 MHz, DMSO-d6, 298 K): δ =146.0, 144.4, 143.7, 
136.2, 133.6, 130.9, 130.4, 127.0, 125.7, 121.9, 54.5. HRMS (ESI) calcd, [C11H11N4O2]
+
 
231.0877; observed, 231.0875. 
 1-(2-Methylallyl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide (10w) 
The title compound was prepared on a 5 mmol scale according to general procedure V 
using 1.1 equiv of 2-methyl-3-bromoprop-1-ene. Purification by precipitation from DCM 
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using diethyl ether followed by column chromatography (silica, DCM/methanol 4:1, 
Rf = 0.28), yielded the product as yellow powder in 91% yield (1.472 g, 4.5 mmol).
 1
H 
NMR (400 MHz, DMSO-d6, 298 K): δ = 10.71 (s, 1H), 9.66 (s, 1H), 8.51 (dd, J = 8.2 
Hz, J = 1.4 Hz, 1H), 8.13 (td, J = 7.6 Hz,  J = 1.5 Hz, 1H), 8.08 (dd, J = 7.9 Hz, J = 1.7 
Hz, 1H), 8.02 (td, J = 7.4 Hz, J = 1.6 Hz, 12H), 5.20 (s, 2H), 5.17 (s, 1H), 5.05 (s, 1H), 




H} NMR (101 MHz, DMSO-d6, 298 K): δ = 145.7, 144.3, 143.3, 
137.7, 135.8, 133.2, 130.4 126.5, 125.2, 116.4, 57.2, 19.4. HRMS (ESI) calcd, 
[C12H13N4O2]
+ 
245.1033; observed, 245.1032. 
 
Section 3.9. General Procedure, Analysis, and Characterization Data for 1-
Substituted-(2-ammoniophenyl)-4H-1,2,4-triazol-1-ium Salts 
Compounds in this section readily decompose when not existing as ammonium salts and 
must be acidified within the day to minimize decomposition. Amines were found to 
decompose on a silica column, although the ammonium salts were never tried. Reduction 
of the nitro group by H2 and Pd/C worked successfully for benzyl substituted triazolium 
with an isolated yield of 63 % on a 2.5 mmol scale, but the palladium-catalyzed reduction 
of aryl-substituted triazolium salts result in ~0% conversion.  
Reduction of Aryl NO2 Triazolium salts (VI) 
2-Nitrophenyl-1,2,4-triazolium salts (1.0 equiv) were mixed with Fe(s) (10 equiv) and 
NH4Cl (10 equiv) in a round-bottomed flask, followed by EtOH/H2O (9:1, 0.02 M). the 
flask was fitted with a condenser and sealed with a septum. The atmosphere was 
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exchanged for argon, and the mixture was stirred at 50 °C for 4 hours with constant 
stirring. 
Workup: Immediately after the reaction was complete, the mixture was diluted with 3x 
the volume of brine and extracted with DCM (3 x 50 mL). The aqueous layer was further 
diluted with 1x the volume of saturated NaHCO3, and the mixture was further extracted 
with DCM (3 x 50 mL). The aqueous layer was further diluted with 1x the volume of 1 M 
NaOH, and the mixture was extracted a third and final time with DCM (3 x 50mL). The 
organic layers were combined, dried (MgSO4), filtered, and concentrated by rotary 
evaporation to yield a crude product. The product was dissolved in a DCM/acetone 
mixture (1:1), and a stir bar was added to the flask. With stirring, 4 M HCl in dioxane 
was added dropwise until 4 equiv of HCl had been added. Diethyl ether was added 
dropwise until no more solid precipitated. The system was allowed to cool to 0 °C 
overnight. The solution was decanted, leaving the ammonium salt to be dried under high 
vacuum.  
Further purification of this salt was carried out by precipitating it from 6 mL of 
methanol/acetone 1:1 with excess diethyl ether or by washing with a 5:1 mixture of 
DCM/acetone. 
Observations: 4-(2-aminophenyl)-4H-1,2,4-triazol-1-ium salts were discovered to be 
unstable if not converted into ammonium salts. The ammonium salt was potentially 
challenging to purify by column chromatography and by solvent extraction. Thus all 1-
substituted-4-(2-aminophenyl)-4H-1,2,4-triazol-1-ium salts were precipitated as 
ammonium salts. If left open to the air, the ammonium salts absorb water and decompose.  
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Testing of Ammonium Salt Ion Composition 
 Exact amounts of the benzyl (55.29 mg), para-fluorophenyl (43.31 mg), para-methoxy-
phenyl (56.97 mg), and para-chlorophenyl (25.77 mg) 4-(2-ammoniophenyl)-4H-1,2,4-
triazol-1-ium salts were mixed with an exact amount of a fluorine-containing standard. 
Sodium trifluoromethylsulfonate was chosen for the benzyl and para-methoxyphenyl 
salts (22.67 mg and 25.50 mg), respectively. Sodium tetrafluoroborate was chosen for 
para-fluorophenyl and para-chlorophenyl salts (106.31 mg and 49.08 mg), respectively. 
The samples were dissolved in enough DMSO-d6 to create a homogeneous solution. The 
19
F NMR analyses indicated no or only trace amounts of the fluorine ions other than the 
standard for each 4-(2-ammoniophenyl)-4H-1,2,4-triazol-1-ium salts. The solutions were 
then diluted in 20 mL of H2O/methanol (1:1). Silver nitrate 2 g was dissolved in 40 mL of 
H2O/methanol (1:1), and 10 mL of this solution was added to each sample, causing the 
silver halide to precipitate. Approximately 10 mL of methanol was added to assist in 
dissolving the organic portion of the molecules. The solutions were centrifuged in vials, 
and the supernatant was decanted from the pellet. The pellet was washed with methanol 
and centrifuged again. The supernatant was decanted from the pellet again and was then 
dried under high vacuum. The following isolated yields of silver chloride were obtained 
(with theoretical yields calculated for the reaction of dichloride anion with silver nitrate) 
benzyl (98.0%), para-fluorophenyl (101.42%), para-methoxyphenyl (93.64%), and para-
chlorophenyl (95.71%). These results were within experimental error and implied that 





Characterization data for the 4-(2-ammoniophenyl)-4H-1,2,4-triazol-1-ium 
chlorides 
4-(2-Ammoniophenyl)-1-benzyl-4H-1,2,4-triazol-1-ium chloride (11n) 
The title compound was prepared on a 5.70 mmol scale according to general procedure 
VI. Purification by precipitating as the ammonium salt from DCM/ether (1:5) then 
washing the solid with DCM/acetone (5:1) yielded the product as a beige solid (95%, 5.4 
mmol, 1.75 g). (DCM/acetone (4:1), Rf = 0.36), 
1
H NMR (400 MHz, DMSO-d6, 298 K): 
δ = 11.00 (s, 1H), 9.52 (s, 1H), 7.59 (dd, J = 7.6 Hz, J = 1.8 Hz, 2H), 7.46 – 7.39 (m, 
4H), 7.34 (td, J = 7.6 Hz, J = 1.5 Hz, 1H) 7.07 (dd, J = 8.3 Hz, J = 1.2 Hz, 1H), 6.81 (td, 




H} NMR (101 MHz, DMSO-d6, 298 K): 
δ = 145.4, 143.9, 142.2, 133.0, 131.9, 129.4, 128.9, 128.8, 127.8, 117.9, 117.8, 117.6, 
54.9. HRMS (ESI) calcd, [C15H15N4]
+
 251.1291; observed, 251.1285. 
 
4-(2-Ammoniophenyl)-1-isopropyl-4H-1,2,4-triazol-1-ium chloride (11o) 
The title compound was prepared on a 3.39 mmol scale according to general procedure 
VI. Purification by precipitating as the ammonium salt from DCM/ether (1:5) then 
washing the solid with DCM/acetone (5:1) yielded the product as an off-white solid 
(99.8%, 3.3 mmol, 932 mg). (DCM/acetone (4:1), Rf = 0. 18), 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 10.63 (s, 1H), 9.47 (s, 1H), 7.36 (dd, J = 8.0 Hz, J = 1.4 Hz, 1H), 
7.33 (td, J = 7.7 Hz, J = 1.4 Hz, 1H), 6.99 (dd, J = 8.0 Hz, J = 1.3 Hz, 1H), 6.77 (td, J = 







NMR (101 MHz, DMSO-d6, 298 K): δ = 144.9, 143.9, 142.4, 141.6, 131.9, 127.9, 118.2, 
118.1, 55.4, 21.2. HRMS (ESI) calcd, [C11H15N4]
+
 203.1291; observed, 203.1288. 
 
4-(2-Ammoniophenyl)-1-(but-3-yn-1-yl)-4H-1,2,4-triazol-1-ium chloride (11p) 
The title compound was prepared on a 3.31 mmol scale according to general procedure 
VI. Purification by precipitating as the ammonium salt from DCM/ether (1:5) then 
washing the solid with DCM/acetone (5:1) yielded the product as off-white solid (99.8% 
yield, 3.3 mmol, 943 mg). (DCM/acetone 4:1, Rf = 0.15), 
1
H NMR (400 MHz, DMSO-d6, 
298 K): δ = 10.77 (s, 1H), 9.52 (s, 1H), 7.35-7.28 (m, 2H), 6.98 (dd, J = 8.2 Hz, J =1.3 
Hz, 1H), 6.74 (td, J = 7.5 Hz, J = 1.3 Hz, 1H), 4.59 (t, J = 7.2 Hz, 2H), 3.10 (t, J = 2.7 




H} NMR (101 MHz, DMSO-d6, 298 
K): δ = 145.2, 144.0, 143.5, 131.9, 127.4, 117.1, 116.8, 116.6, 79.7, 74.2, 50.2, 18.3. 
HRMS (ESI) calcd, [C12H13N4]
+ 
213.1135; observed, 213.1130. 
 
4-(2-Ammoniophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium chloride (11q) 
The title compound was prepared on a 2.0 mmol scale according to general procedure VI. 
Purification by precipitating as the ammonium salt from DCM/ether (1:5) then washing 
the solid with DCM/acetone (5:1) yielded the product as an off-white solid (78%, 1.5 
mmol, 479 mg). (DCM/acetone (4:1), Rf = 0.28), 
1
H NMR (400 MHz, DMSO-d6, 298 K): δ 
= 11.51 (s, 1H), 9.76 (s, 1H), 8.06 (d, J = 7.1 Hz, 2H), 7.72 (t, J = 7.6 Hz, 2H), 7.64 (t, J = 7.4 
Hz, 1H), 7.49 (dd, J = 7.9 Hz, J = 1.5 Hz, 1H), 7.38 (td, J = 7.7 Hz, J = 1.5 Hz, 1H), 




H} NMR (101 
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MHz, DMSO-d6, 298 K): δ = 145.9, 143.1, 142.9, 135.6, 132.5, 131.0, 130.6, 128.3, 121.3, 118.2, 
118.0, 117.9. HRMS (ESI) calcd, [C14H13N4]
+
 237.1135; observed, 237.1130. 
 
4-(2-Ammoniophenyl)-1-mesityl-4H-1,2,4-triazol-1-ium chloride (11r) 
The title compound was prepared on a 2.55 mmol scale according to general procedure 
VI. Purification by precipitating as the ammonium salt from DCM/ether (1:5) then 
washing the solid with DCM/acetone (5:1) yielded the product as an off-white solid 
(43%, 1.09 mmol, 383 mg). (DCM/acetone (4:1), Rf = 0.34), 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 11.01 (s, 1H), 9.84 (s, 1H), 7.51 (dd, J = 7.9 Hz, J = 1.5 Hz, 1H), 
7.37 (td, J = 7.8 Hz, J = 1.5 Hz, 1H), 7.18 (s, 2H), 7.05 (d, J = 8.2 Hz, 1H), 




H} NMR (101 
MHz, DMSO-d6, 298 K): δ = 146.04, 145.25, 142.40, 141.22, 134.80, 132.05, 131.09, 
129.61, 128.06, 118.26, 117.92, 117.72, 20.71, 17.43. HRMS (ESI) calcd, [C17H19N4]
+
 
279.1604; observed, 279.1598. 
 
4-(2-Ammoniophenyl)-1-(4-methoxyphenyl)-4H-1,2,4-triazol-1-ium chloride (11s) 
The title compound was prepared on a 5 mmol scale according to general procedure VI. 
Purification by precipitating as the ammonium salt from DCM/ether (1:5) then washing 
the solid with DCM/acetone (5:1) yielded the product as tan powder (81%, 4.03 mmol, 
1.37 g). (DCM/acetone (4:1), Rf = 0.31), 
1
H NMR (400 MHz, DMSO-d6, 298 K): δ = 11.28 
(s, 1H), 9.68 (s, 1H), 7.95 (d, J = 9.1 Hz, 2H), 7.45 (dd, J = 8.1 Hz, J = 1.5 Hz, 1H), 7.36 (td, J = 
7.7 Hz, J = 1.5 Hz, 1H), 7.26 (d, J = 9.1 Hz, 2H), 7.03 (dd, J = 8.1 Hz, J = 1.1 Hz, 1H), 6.80 (td, 
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H} NMR (101 MHz, DMSO-d6, 298 K): δ = 
160.6, 145.4, 143.2, 141.8, 132.1, 128.2, 127.8, 122.6, 117.3, 117.1, 116.8, 115.2, 55.9. HRMS 
(ESI) calcd, [C15H15N4O]
+
 267.1240; observed, 267.1234. 
 
4-(2-Ammoniophenyl)-1-(4-fluorophenyl)-4H-1,2,4-triazol-1-ium chloride (11t) 
The title compound was prepared on a 2 mmol scale according to general procedure VI. 
Purification by precipitating as the ammonium salt from DCM/ether (1:5) then washing 
the solid with DCM/acetone (5:1) yielded the product as an off-white powder (77%, 
1.55 mmol, 506 mg). (DCM/acetone (4:1), Rf = 0.31), 
1
H NMR (400 MHz, DMSO-d6, 
298 K): δ = 11.42 (s, 1H), 9.73 (s, 1H), 8.10 (dd, J = 9.1 Hz, J = 4.6 Hz, 2H), 7.61 (t, J = 
8.7 Hz, 2H), 7.45 (dd, J = 7.8 Hz, J = 1.2 Hz, 1H), 7.37 (ddd, J = 8.7 Hz, J = 7.3 Hz, J = 





NMR (101 MHz, DMSO-d6, 298 K): δ = 162.6 (d, JC-F = 248.0 Hz), 145.5, 143.2, 142.8, 
132.1, 131.6 (d, JC-F = 3.0 Hz), 127.8, 127.7, 123.5 (d, JC-F = 9.3 Hz), 117.3, 117.1, 116.9 
(d, JC-F = 14.3 Hz); 
19
F NMR (376 MHz, DMSO-d6) δ = -110.23. HRMS (ESI) calcd, 
[C14H12FN4]
+
 255.1041; observed, 255.1036. 
 
4-(2-Ammoniophenyl)-1-(4-chlorophenyl)-4H-1,2,4-triazol-1-ium chloride (11u) 
The title compound was prepared on a 2.0 mmol scale according to general procedure VI. 
Purification by precipitating as the ammonium salt from DCM/ether (1:5) then washing 
the solid with DCM/ acetone (5:1) yielded the product as an off-white powder (54%, 1.07 
mmol, 371 mg). (DCM/acetone (4:1), Rf = 0.31), 
1
H NMR (400 MHz, DMSO-d6, 298 K): 
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δ = 11.53 (s, 1H), 9.76 (s, 1H), 8.09 (d, J = 8.9 Hz, 2H), 7.83 (d, J = 8.9 Hz, 2H), 
7.48 (dd, J = 8.0 Hz, J = 0.8 Hz, 1H), 7.38 (ddd, J = 7.8 Hz, J = 1.3 Hz, J = 1.0 Hz, 1H), 




H} NMR (101 MHz, DMSO-d6, 
298 K): δ =145.6, 143.1, 142.6, 135.0, 133.9, 132.2, 130.2, 127.9, 127.8, 122.7, 117.7, 
117.4. HRMS (ESI) calcd, [C14H12ClN4]
+
 271.0745; observed, 271.0741. 
 
1-Allyl-4-(2-ammoniophenyl)-4H-1,2,4-triazol-1-ium chloride (11v) 
 The title compound was prepared on a 2.0 mmol scale according to general procedure 
VI. Purification by precipitating as the ammonium salt from DCM/ether (1:5) then 
washing the solid with DCM/acetone (5:1) yielded the product as an off-white powder 
(76%, 1.52 mmol, 415 mg). (DCM/acetone (4:1), Rf = 0.20), 
1
H NMR (400 MHz, 
DMSO-d6, 298 K): δ = 10.77 (s, 1H), 9.52 (s, 1H), 7.41 – 7.33 ((dd, J = 7.9 Hz, 
J = 1.3 Hz), (dd, J = 7.4 Hz, J = 1.5 Hz), 2H), 7.07 (dd, J = 8.2 Hz, J = 1.2 Hz, 1H), 
6.83 (td, J = 7.6 Hz, J = 1.2 Hz, 1H), 6.13 (ddt, J = 17.1 Hz, J = 10.3 Hz, J = 6.2 Hz, 
1H), 5.56 (dd, J = 17.1 Hz, J = 1.2 Hz, 1H), 5.45 (dd, J = 10.3 Hz, J = 1.2 Hz, 1H), 5.12 




H} NMR (101 MHz, DMSO-d6, 298 K): δ = 145.2, 143.8, 
141.9, 131.9, 130.0, 127.8, 121.6, 118.0, 117.9, 117.8, 53.9. HRMS (ESI) calcd, 
[C11H13N4]
+
 201.1135; observed, 201.1134. 
 
4-(2-Ammoniophenyl)-1-(2-methylallyl)-4H-1,2,4-triazol-1-ium chloride (11w) 
 The title compound was prepared on a 2.05 mmol scale according to general procedure 
VI. Purification by precipitating as the ammonium salt from DCM/ether (1:5) then 
washing the solid with DCM/acetone (5:1) yielded the product as an off-white powder 
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(99%, 2.01 mmol, 580 mg). (DCM/acetone (4:1), Rf = 0.26), 
1
H NMR (400 MHz, DMSO-
d6, 298 K): δ = 10.87 (s, 1H), 9.59 (s, 1H), 7.46 (dd, J = 8.0 Hz, J = 1.4 Hz, 1H), 7.39 (td, J = 7.8 
Hz, J = 1.4 Hz, 1H), 7.14 (dd, J = 8.0 Hz, J = 1.1 Hz, 1H), 6.89 (td, J = 7.8 Hz, J = 1.1 Hz, 1H), 




H} NMR (101 MHz, DMSO-d6, 298 
K): δ = 145.3, 144.1, 141.0, 137.6, 132.0, 127.9, 126.0, 118.6, 118.5, 117.0, 57.2, 19.9. HRMS 
(ESI) calcd, [C12H15N4]
+
 215.1291; observed, 215.1290. 
 
Section 3.10: General Procedure and Characterization Data for 
9H-Benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium Salts 
2.5 Synthesis of benzoimidazole triazolium salts ( General Procedure VII) 
Iodine (1.5-2.0 equiv) and freshly washed 1-substituted-4-(2-ammoniophenyl)-4H-1,2,4-
triazol-1-ium chloride (1.0 equiv) were added to a round-bottomed flask, which was then 
equipped with a condenser. The solids were suspended in DCM (0.02 M), and then DBU 
(4.0 equiv) was injected. The atmosphere was exchanged for argon, and the reaction 
mixture was allowed to stir at reflux for 4 h. 
Workup: The mixture was concentrated by rotary evaporation. The product was loaded 
onto a silica column and eluted using hexane-acetone (4:1) with an incremental 5% 
increase in acetone until the compound eluted, which was usually around 20-25% 
acetone. A 1:1 mixture of hexanes/acetone was used to force any remaining compound 
from the silica column. TLC was used to determine pure fractions, which were then 
collected and concentrated by rotary evaporation. The purified fractions were then eluted 
through a 30 cm x 2 cm column loaded with the ion exchange resin, amberlyst 15 (eluted 
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, 50 mL H2O) Silver nitrate test was 
carried out on test samples to ensure complete conversion to triflate.  
Observations: LCMS analysis of test reaction at 1 h, 2 h, 4 h, and 8 h, indicated that 
complete consumption of the starting material had been reached at 1 h. However, 
reactions were allowed to react for 4 hours to ensure complete conversion for deactivated 
systems.  
 
Characterization data for 9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium salts 
1-Benzyl-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium trifluoromethanesulfonate 
(12n) 
 The title compound was prepared on a 1.13 mmol scale according to general procedure 
VII. Purification by column chromatography (silica, hexane/acetone (4:1), Rf = 0.14), 
followed by elution through an ion exchange column, yielded the product as an off-white 
powder (46%, 0.52 mmol, 208 mg). 1H NMR (400 MHz, CDCl3, 298 K) δ = 8.32 (s, 1H), 7.72 
(d, J = 8.2 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.46 (dd, J = 8.0 Hz, J = 1.6 Hz, 2H), 7.41 (td, 
J = 7.8 Hz, J = 1.1 Hz, 1H), 7.38 – 7.30 (unresolved m, 3H), 7.21 (td, J = 7.8 Hz, J = 0.8 Hz, 




H} NMR (101 MHz, CDCl3, 298 K) δ = 153.3, 149.3, 135.20, 129.0, 
128.5, 128.4, 127.3, 125.3, 125.1, 119.8, 118.7, 111.3, 52.1. HRMS (ESI) calcd, [C15H14N4]
+
 






 The title compound was prepared on a 1.0 mmol scale according to general procedure 
VII. Purification by column chromatography (silica, hexane/acetone (4:1), Rf = 0.18), 
followed by elution through an ion exchange column, yielded the product as an off-white 
powder (63%, 0.63 mmol, 220 mg). 
1
H NMR (400 MHz, CDCl3, 298 K) δ = 8.79 (s, 1H), 
7.91 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.3 Hz, 1H), 7.57 (td, J = 7.9 Hz, J = 1.1 Hz, 1H), 





H} NMR (151 MHz, CDCl3, 298 K) δ = 145.2, 136.9, 130.0, 128.5, 124.5, 121.9, 
115.8, 113.3, 54.3, 21.4. HRMS (ESI) calcd, [C11H13N4]
+ 




 The title compound was prepared on a 1.0 mmol scale according to general procedure 
VII. Purification by column chromatography (silica, hexane/acetone (7:3), Rf = 0.33), 
followed by elution through an ion exchange column, yielded the product as tan powder 
(53%, 0.53 mmol, 190 mg). 
1
H NMR (400 MHz, CDCl3, 298 K) δ = 8.80z (s, 1H), 7.92 
(d, J = 8.2 Hz, 1H), 7.79 (d, J = 8.3 Hz, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.49 (t, J = 7.6 Hz, 





H} NMR (101 MHz, CDCl3, 298 K) δ = 146.6, 137.0, 130.4, 128.7, 124.7, 









 The title compound was prepared on a 1.2 mmol scale  according to general procedure 
VII. Purification by column chromatography (silica, hexane/acetone (4:1), Rf = 0.35), 
followed by elution through a ion exchange column, yielded the product as off-white 
powder (20%, 0.24 mmol, 90 mg). 
1
H NMR (400 MHz, CDCl3, 298 K) δ = 8.43 (s, 1H), 
8.25 (d, J = 8.0 Hz, 2H), 7.81 (d, J = 8.2 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.54 (t, J = 
8.0 Hz, 2H), 7.44 (td, J = 7.8 Hz, J = 1.1 Hz, 1H), 7.31 – 7.22 (Unresolved t, 1H), 




H} NMR (101 MHz, CDCl3, 298 K) δ = 151.0, 
149.2, 137.5, 129.6, 127.9, 125.8, 125.5, 124.4, 120.6, 119.2, 117.5, 111.3. HRMS (ESI) 
calcd, [C14H11N4]
+




 The title compound was prepared on a 1.32 mmol scale according to general procedure 
VII. Purification by column chromatography (silica, hexane/acetone (4:1), Rf = 0.32), 
followed by elution through an ion exchange column, yielded the product as an off-white 
powder (39%, 0.52 mmol, 221 mg). 1H NMR (400 MHz, CDCl3, 298 K) δ = 8.47 (s, 1H), 7.72 
(d, J = 8.0 Hz, 1H), 7.67 (d, J = 8.2 Hz, 1H), 7.39 (td, J = 7.7 Hz, J = 1.2 Hz, 1H), 7.21 (td, 




H} NMR (101 MHz, 
CDCl3, 298 K) δ = 153.5, 150.7, 140.1, 136.8, 131.5, 129.5, 127.7, 125.5, 125.1, 119.5, 119.3, 
111.2, 21.3, 17.9. HRMS (ESI) calcd, [C17H17N4]
+






 The title compound was prepared on a 1.15 mmol scale according to general procedure 
VII. Purification by column chromatography (silica, hexane/acetone (4:1), Rf = 0.27), 
followed by elution through an ion exchange column, yielded the product as a white 
powder (24%, 0.27 mmol, 112 mg). 1H NMR (400 MHz, CDCl3, 298 K) δ = 8.40 (s, 1H), 8.12 
(d, J = 9.1 Hz, 2H), 7.78 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.42 (ddd, J = 8.2 Hz, J = 
7.5 Hz, J = 1.1 Hz, 1H), 7.23 (ddd, , J = 8.0 Hz, J = 7.8 Hz, J = 1.0 Hz, 1H), 7.05 (d, J = 9.1 Hz, 




H} NMR (101 MHz, CDCl3, 298 K) δ = 157.6, 151.6, 150.3, 131.3, 
127.2, 125.3, 124.8, 120.1, 119.5, 119.1, 114.8, 111.1, 55.8. HRMS (ESI) calcd, [C15H13N4O]
+
 




 The title compound was prepared on a 1.34 mmol scale according to general procedure 
VII. Purification by column chromatography (silica, hexane/acetone (4:1), Rf = 0.36), 
followed by elution through an ion exchange column, yielded the product as a white 
powder (32%, 0.43 mmol, 172 mg). 1H NMR (400 MHz, CDCl3, 298 K) δ = 8.43 (s, 1H), 8.23 
– 8.17 (m, J = 9.1 Hz, J = 7.0 Hz, J = 6.8 Hz, 2H), 7.79 (d, J = 8.2 Hz, 1H), 7.70 (d, J = 8.0 Hz, 




H} NMR (101 MHz, 
CDCl3, 298 K) δ = 160.4 (d, JC-F = 245.5 Hz), 151.3, 149.9, 133.9 (d, JC-F = 2.9 Hz), 127.8, 125.5, 
124.7, 120.5, 119.5, 119.2 (d, JC-F = 8.2 Hz), 116.4 (d, JC-F = 23.2 Hz), 111.2; 
19
F NMR (376 
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MHz, CDCl) δ = -78.52, -116.51. HRMS (ESI) calcd, [C14H10FN4]
+





The title compound was prepared on a 1.33 mmol scale according to general procedure 
VII. Purification by column chromatography (silica, hexane/acetone (4:1), Rf = 0.43), 
followed by elution through an ion exchange column, yielded the product as a tan powder 
12% yield, 0.16 mmol, 68 mg). 1H NMR (400 MHz, CDCl3, 298 K) δ =8.43 (s, 1H), 8.18 (d, J 
= 8.9 Hz, 2H), 7.79 (d, J = 8.3 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.9 Hz, 2H), 7.44 




H} NMR (101 MHz, CDCl3, 298 K) δ = 151.1, 
149.6, 136.2, 131.1, 129.7, 128.0, 125.7, 124.6, 120.8, 119.5, 118.7, 111.3. HRMS (ESI) calcd, 
[C14H10ClN4]
+




The title compound was prepared on a 1.0 mmol scale according to general procedure 
VII. Purification by column chromatography (silica, hexane/acetone (4:1), Rf = 0.14), 
followed by elution through an ion exchange column, yielded the product as an off-white 
powder (43%, 0.43 mmol, 148 mg). 1H NMR (400 MHz, CDCl3, 298 K) δ = 8.54 (s, 1H), 7.77 
(d, J = 8.1 Hz, 1H), 7.71 (d, J = 8.3 Hz, 1H), 7.46 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 7.30 (td, 
J = 7.4 Hz, J =1.0 Hz, 1H), 6.05 (ddt, J = 17.0 Hz, J = 10.1 Hz, J = 6.1 Hz, 2H), 5.47 (dd, 







H} NMR (101 MHz, CDCl3, 298 K) δ =  148.7, 141.7, 129.3, 129.3, 127.3, 123.3, 122.7, 
121.8, 116.8, 112.7, 52.0. HRMS (ESI) calcd, [C11H11N4]
+




 The title compound was prepared on a 1.0 mmol scale according to general procedure 
VII. Purification by column chromatography (silica, hexane/acetone (4:1), Rf = 0.21), 
followed by elution through ion exchange column, yielded the product as an off-white 
powder (35%, 0.35 mmol, 125 mg). 1H NMR (400 MHz, CDCl3, 298 K) δ = 8.83 (s, 1H), 7.93 
(d, J = 8.2 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.57 (t, J = 8.2 Hz, 1H), 7.47 (t, J = 8.2 Hz, 1H), 




H} NMR (101 MHz, CDCl3, 298 K) δ 
= 146.3, 137.1, 136.7, 130.2, 128.7, 124.6, 122.1, 117.6, 116.0, 113.3, 56.1, 20.0. HRMS (ESI) 
calcd, [C12H13N4]
+










We have developed novel methods for synthesizing triazole-containing heterocycles. 
Beginning from amines, we were able to access novel 1,4-disubstituted-1,2,4-triazolium 
salts rapidly through a two-step synthesis, first progressing through the 4-substituted-
1,2,4-triazoles, and finally using a copper-catalyzed N-arylation to access the final 
product. The 1,2,4-triazole formation progressed in low to moderate yields (7.4-73%), but 
was considered acceptable due to the low cost of the starting materials. The copper-
catalyzed arylation progressed in higher yields; triazoles containing heterocycles, 
aliphatic groups, sterically hindered aryl groups, and haloaryl groups were all arylated 
with moderate to excellent yields (58-99%). We were also able to introduce various aryl 
groups at this late stage, including electron-withdrawing, electron-donating, sterically 
hindered, fluorine-containing, and non-functionalized aryl groups. All resulted in 
moderate to high yields (52-96%). Arylating various triazoles with a mesityl group 
resulted in the formation of the desired products in moderate yields (54-86%). These 
yields were acceptable compared to the 8% yield we obtained when the compounds were 
synthesized via the traditional method. 
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The preparation of unsymmetrically substituted electron-rich carbene precursors, 
sterically hindered electron-poor 1,2,4-triazolium salts, and electron-rich pyrimidine 
derivatives were realized cleanly in moderate to high yields (53-98%). 1,4-Substituted-
1,2,4-triazolium salts containing a mesityl group were challenging to separate from the 
starting materials via column chromatography, and incorporation of heterocycles such as 
pyridine and pyrimidine caused the resulting 1,4-substituted-1,2,4-triazolium salt to 
decompose on or strongly bond to the silica gel. Despite occasional difficulties in 
purification, our copper-catalyzed arylation allows access to previously unobtainable, 
unsymmetrically substituted triazolium precatalysts and ligands, with the potential to 
easily vary the steric and electronic parameters of the resulting NHCs. In the future, we 
plan to synthesize 1,2,4-triazole containing transition metal complexes, varying the steric 
and electronic effects around the metal center; we hope to discover an efficient catalyst 
for the Suzuki, Heck, or Sonogashira coupling reaction. We also plan to determine the 
organocatalytic efficiency of our synthesized 1,4-disubstitued-1,2,4-triazolium salts for 
the benzoin condensation or the Stetter reaction.  Our method also allows for 1,2,4-
triazolium salts to become more abundant in research, potentially elucidating new 
reactions and more efficient methods.    
We set out to synthesize various 9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 
triflates via iodine promoted C–H activation. Starting from 4-(2-nitrophenyl)-1,2,4-
triazole, we synthesized several 4-(2-nitrophenyl)-1-(aryl)-1,2,4-triazolium salts in 
moderate to high yields (82-94%) and 4-(2-nitrophenyl)-1-(alkyl)-1,2,4-triazolium 
bromides also in moderate to high yields (80-91%). The 4-(2-nitrophenyl)-1-substituted-
1,2,4-triazolium salts were first reduced by iron(0) under acidic conditions and then 
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isolated and stored as the HCl derivative. We were able to isolate various 4-(2-
ammoniophenyl)-[1,2,4]-triazol-1-ium chlorides in moderate to high yields (42-99%). By 
subjecting these substrates to our optimized conditions, we found that the C–H activation 
progressed in low to moderate yields (12-63%). Aliphatic substituted triazoles cyclized 
with higher yields (34-63%), with groups including alkenes and alkynes being tollerated.. 
Aryl-substituted triazoles had much lower yields (12-39%), with the para-chlorophenyl 
and unsubstituted phenyl systems giving the lowest yields: 12% and 19%, respectively. 
Para-trifluoromethyl phenyl substituted triazolium salts failed to cyclize and resulted in 
decomposition instead, implying that strongly electron-withdrawing substituents are not 
tolerated. We observed that the 4-(2-nitrophenyl)-1-phenyl-[1,2,4]-triazol-1-ium triflate 
underwent reductive cyclization more readily. Despite the lower than desired yields, this 
method allows for a relatively efficient and straightforward method for the acquisition of 
novel substituted 9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium salts. Further 
development of the method would be necessary to derive a more generalized reaction. 
However, optimization for specialized substrates, better solvent-substrate pairing, and 
additives to stabilize the amine could increase isolated yields. Testing the biological activity 
of our 9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium salts against various bacteria, 
fungus, viruses, and tumors/ cancers would be the most logical next course of action. We 
could also further functionalize our structural motif and determine these substrates' 
biological activity. Structure-activity relationship studies could be undertaken if we find 
that our imidazo triazolium salts display potent biological activity against certain classes 
of microbes or tumors. We are confident that we have developed novel methods for the 
arylation of 4-substituted-1,2,4-triazoles and incorporating 1,2,4-triazolium salts into poly 
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heterocyclic systems. These advancements will allow for easier development of novel 
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APPENDIX A: GENERAL INFORMATION 
Most reagents and solvents were obtained from commercial sources and used as supplied 
unless otherwise noted. Acetonitrile used for catalytic reactions was dried under an inert 











H} NMR spectra were all 
recorded on a 400 MHz Bruker Avance III spectrometer with a 5 mm liquid-state Smart 
Probe. Chemical shifts (δH and δC) are expressed in parts per million (ppm) and reported 
relative to the resonance of the residual protons of the DMSO-d6 (δH = 2.50 ppm) or 




H} NMR spectra relative to the resonance of the 
deuterated solvent DMSO-d6 (δC = 39.52 ppm) or CDCl3 (δC = 77.16 ppm). Chemical 
shifts in 
19
F{1H} NMR spectra are reported relative to the internal standard 
fluorobenzene (δF = −113.15). Coupling constants (J) are given in Hz. All measurements 
were carried out at 298 K. Abbreviations used in the description of NMR data are as 
follows: s, singlet; d, doublet; t, triplet; q, quartet; sept, septet; and m, multiplet. High-
Resolution Mass Spectrometry (HRMS) data were obtained on an LTQ Orbitrap XL in 
FT Orbitrap mode at a resolution of 100,000. 
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APPENDIX B: COMMON ABBREVIATIONS 
DMF – Dimethylformamide  
DCM – Dichloromethane, methylene chloride  
DCE – 1,2-Dichloroethane   
CDCl3 – Deuterated chloroform  
DMSO-d6 – Deuterated dimethylsulfoxide  
FDA – Food and drug Administration 
DNA– Deoxyribose nucleic acid  
RNA– Ribose nucleic acid 
PPAR α/β– Peroxisome Proliferator Activated Receptor Alpha / Beta 
NHC– N-Heterocyclic Carbene 
ee– Enantiomeric Excess 
DBU– 1,8-Diazabicyclo[5.4.0]undec-7-ene 
THF– Tetrahydrofuran 
EWG– Electron Withdrawing Group 
m-CPBA– meta-Chloroperoxybenzoic acid 
DMSO– Dimethylsulfoxide 
phen– Phenanthroline 
equiv. – Equivalents  
HRMS– High Resolution Mass Spectroscopy  
LCMS– Liquid Chromatography–Mass Spectrometry 
NMR– Nuclear Magnetic Resonance Spectroscopy 
M.S. – Molecular Sieves  
rt– Room Temperature  
DME– Dimethoxyethane 
NEt3– Triethylamine 
Ac2O– Acetic Anhydride 
i-PrOH– Isopropanol  
MeOH– Methanol 
OTf– Trifluoromethanesulfonyloxy (Triflate) 
BF4– Tetrafluoroborate 
Pd/C– Palladium on Carbon 
Cu(OAc) – Cupric Acetate / Copper (I) Acetate 
Cu(OAc)2– Cuprous Acetate / Copper (II) Acetate 
Cu(OTf)2– Cuprous triflate / Copper (II) Triflate 
DMAZ– N,N-Dimethylformamide Azine Dihydrochloride 
HCO2H– Formic Acid 
PTSA, TsOH– p-Toluenesulfonic Acid 
CHCl3– Chloroform 
MECN, MeCN– Acetonitrile 
HClO4– Perchloric acid 
NaIO4– Sodium Periodate 
[Ir(dncot)Cl]2– Iridium (I) Dinaphthocyclooctatetraene chloride Dimer 
PhI(OAc)2–  (Diacetoxyiodo)benzene / Phenyliodine(III) Diacetate 
Sc(OTf)3– Scandium Trifluoromethanesulfonate/ Scandium (III) Triflate 
HC(OEt)3– Triethyl Orthoformate 
Me3OBF4– Trimethyloxonium Tetrafluoroborate 
NaOEt– Sodium Ethoxide 
EtOH – Ethanol 
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APPENDIX D: SPECTRA FOR CHAPTER 2 
 
Section D.1: NMR Yields for 1,4-Disubstituted-1,2,4-triazolium Salts (D001-D033) 
 





Figure D002: NMR yield of crude 4-cyclohexyl-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 
([2b]BF4) 
 





Figure D004: NMR yield of crude 1,4-diphenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2d]BF4) 
 





Figure D006: NMR yield of crude 4-(2,6-diisopropylphenyl)-1-phenyl-4H-1,2,4-triazol-1-ium 
tetrafluoroborate ([2e]BF4) 
 





Figure D008: NMR yield of crude 4-(2-fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 
([2g]BF4) 
 





Figure D010: NMR yield of crude 4-(4-fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 
([2i]BF4) 
 





Figure D012: NMR yield of crude 4-(4-chlorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 
([2k]BF4) 
 





Figure D014: NMR yield of crude 1-phenyl-4-(pyrimidin-2-yl)-4H-1,2,4-triazol-1-ium tetrafluoroborate 
([2m]BF4) 
 





Figure D016: NMR yield of crude 4-(2-chlorophenyl)-1-(o-tolyl)-4H-1,2,4-triazol-1-ium 
trifluoromethanesulfonate ([3j]OTf) 
 





Figure D018: NMR yield of crude 4-cyclohexyl-1-mesityl-4H-1,2,4-triazol-1-ium 
trifluoromethanesulfonate ([4b]OTf) 
 





Figure D020: NMR yield of crude 1-mesityl-4-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([4d]BF4) 
 





Figure D022: NMR yield of crude 1-mesityl-4-(2-((4-methoxybenzyl)thio)phenyl)-4H-1,2,4-triazol-1-ium 
trifluoromethanesulfonate ([4f]OTf) 
 





Figure D024: NMR yield of crude 4-(4-chlorophenyl)-1-mesityl-4H-1,2,4-triazol-1-ium 
trifluoromethanesulfonate ([4k]OTf) 
 





Figure D026: NMR yield of crude 4-cyclohexyl-1-(naphthalen-1-yl)-4H-1,2,4-triazol-1-ium 
tetrafluoroborate ([5b]BF4) 
 





Figure D028: NMR yield of crude 1-(4-methoxyphenyl)-4-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 
([6d]BF4) 
 





Figure D030: NMR yield of crude 4-phenyl-1-(3-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-1-ium 
tetrafluoroborate ([7d]BF4) 
 
Figure D031: NMR yield of crude 4-(2,6-diisopropylphenyl)-1-(3-(trifluoromethyl)phenyl)-4H-1,2,4-




Figure D032: NMR yield of crude 1-(4-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-1-ium 
trifluoromethanesulfonate ([8d]OTf) 
 








H NMR spectrum of 4-benzyl-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2a]BF4) 




C NMR spectrum of 4-benzyl-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2a]BF4) 






H NMR spectrum of 4-cyclohexyl-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 




C NMR spectrum of 4-cyclohexyl-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 







H NMR spectrum of 4-((3s,5s,7s)-adamantan-1-yl)-1-phenyl-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 4-((3s,5s,7s)-adamantan-1-yl)-1-phenyl-4H-1,2,4-triazol-1-ium 







H NMR spectrum of 1,4-diphenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2d]BF4) 




C NMR spectrum of 1,4-diphenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([2d]BF4) 







H NMR spectrum of 1,4-diphenyl-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate 




C NMR spectrum of 1,4-diphenyl-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate 







H NMR spectrum of 4-(2,6-diisopropylphenyl)-1-phenyl-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 4-(2,6-diisopropylphenyl)-1-phenyl-4H-1,2,4-triazol-1-ium 







H NMR spectrum of 1-phenyl-4-(2-((4-methoxybenzyl)thio)phenyl)-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 1-phenyl-4-(2-((4-methoxybenzyl)thio)phenyl)-4H-1,2,4-triazol-1-







H NMR spectrum of 4-(2-fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 




C NMR spectrum of 4-(2-fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 







F NMR spectrum of 4-(2-fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 




H NMR spectrum of 4-(3-fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 






C NMR spectrum of 4-(3-fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 




F NMR spectrum of 4-(3-fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 






H NMR spectrum of 4-(4-fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 




C NMR spectrum of 4-(4-fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 







F NMR spectrum of 4-(4-fluorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 




H NMR spectrum of 4-(2-chlorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 







C NMR spectrum of 4-(2-chlorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 




H NMR spectrum of 4-(4-chlorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 







C NMR spectrum of 4-(4-chlorophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 




H NMR spectrum of 1-phenyl-4-(pyridin-2-yl)-4H-1,2,4-triazol-1-ium tetrafluoroborate 







C NMR spectrum of 1-phenyl-4-(pyridin-2-yl)-4H-1,2,4-triazol-1-ium tetrafluoroborate 




H NMR spectrum of 1-phenyl-4-(pyrimidin-2-yl)-4H-1,2,4-triazol-1-ium tetrafluoroborate 







C NMR spectrum of 1-phenyl-4-(pyrimidin-2-yl)-4H-1,2,4-triazol-1-ium tetrafluoroborate 




H NMR spectrum of 4-phenyl-1-(o-tolyl)-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate 






C NMR spectrum of 4-phenyl-1-(o-tolyl)-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate 




H NMR spectrum of 4-(2-chlorophenyl)-1-(o-tolyl)-4H-1,2,4-triazol-1-ium 






C NMR spectrum of 4-(2-chlorophenyl)-1-(o-tolyl)-4H-1,2,4-triazol-1-ium 




H NMR spectrum of 4-benzyl-1-mesityl-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate 






C NMR spectrum of 4-benzyl-1-mesityl-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate 




H NMR spectrum of4-cyclohexyl-1-mesityl-4H-1,2,4-triazol-1-ium 






C NMR spectrum of 4-cyclohexyl-1-mesityl-4H-1,2,4-triazol-1-ium 




H NMR spectrum of 4-((3s,5s,7s)-adamantan-1-yl)-1-mesityl-4H-1,2,4-triazol-1-ium 






C NMR spectrum of 4-((3s,5s,7s)-adamantan-1-yl)-1-mesityl-4H-1,2,4-triazol-1-ium 




H NMR spectrum of 1-mesityl-4-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate ([4d]BF4) 






C NMR spectrum of 1-mesityl-4-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 




H NMR spectrum of 1-mesityl-4-phenyl-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate 






C NMR spectrum of 1-mesityl-4-phenyl-4H-1,2,4-triazol-1-ium trifluoromethanesulfonate 




H NMR spectrum of 1-mesityl-4-(2-((4-methoxybenzyl)thio)phenyl)-4H-1,2,4-triazol-1-






C NMR spectrum of 1-mesityl-4-(2-((4-methoxybenzyl)thio)phenyl)-4H-1,2,4-triazol-1-




H NMR spectrum of 4-(4-fluorophenyl)-1-mesityl-4H-1,2,4-triazol-1-ium 






C NMR spectrum of 4-(4-fluorophenyl)-1-mesityl-4H-1,2,4-triazol-1-ium 




F NMR spectrum of 4-(4-fluorophenyl)-1-mesityl-4H-1,2,4-triazol-1-ium 






H NMR spectrum of 4-(4-chlorophenyl)-1-mesityl-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 4-(4-chlorophenyl)-1-mesityl-4H-1,2,4-triazol-1-ium 






H NMR spectrum of 1-mesityl-4-(pyridin-2-yl)-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 1-mesityl-4-(pyridin-2-yl)-4H-1,2,4-triazol-1-ium 







H NMR spectrum of 4-cyclohexyl-1-(naphthalen-1-yl)-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 4-cyclohexyl-1-(naphthalen-1-yl)-4H-1,2,4-triazol-1-ium 







H NMR spectrum of 1-(naphthalen-1-yl)-4-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 




C NMR spectrum of 1-(naphthalen-1-yl)-4-phenyl-4H-1,2,4-triazol-1-ium tetrafluoroborate 







H NMR spectrum of 1-(4-methoxyphenyl)-4-phenyl-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 1-(4-methoxyphenyl)-4-phenyl-4H-1,2,4-triazol-1-ium 






H NMR spectrum of 1-(4-methoxyphenyl)-4-(pyrimidin-2-yl)-4H-1,2,4-triazol-1-ium 
tetrafluoroborate ([6m]BF4) (400 MHz, DMSO-d6, 298 K). The impurities around 6.6 ppm were introduced 




C NMR spectrum of 1-(4-methoxyphenyl)-4-(pyrimidin-2-yl)-4H-1,2,4-triazol-1-ium 







H NMR spectrum of 4-phenyl-1-(3-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 4-phenyl-1-(3-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-1-ium 







F NMR spectrum of 4-phenyl-1-(3-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-1-ium 




H NMR spectrum of 4-(2,6-diisopropylphenyl)-1-(3-(trifluoromethyl)phenyl)-4H-1,2,4-






C NMR spectrum of 4-(2,6-diisopropylphenyl)-1-(3-(trifluoromethyl)phenyl)-4H-1,2,4-




F NMR spectrum of 4-(2,6-diisopropylphenyl)-1-(3-(trifluoromethyl)phenyl)-4H-1,2,4-






H NMR spectrum of 1-(4-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 1-(4-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-1-ium 






F NMR spectrum of 1-(4-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-1-ium 




H NMR spectrum of 4-(2,6-diisopropylphenyl)-1-(4-fluorophenyl)-4H-1,2,4-triazol-1-ium 







C NMR spectrum of 4-(2,6-diisopropylphenyl)-1-(4-fluorophenyl)-4H-1,2,4-triazol-1-ium 





F NMR spectrum of 4-(2,6-diisopropylphenyl)-1-(4-fluorophenyl)-4H-1,2,4-triazol-1-ium 
trifluoromethanesulfonate ([8e]OTf) (376 MHz, DMSO-d6, 298 K, referenced to fluorobenzene). 
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APPENDIX E: SPECTRA FOR CHAPTER 3 
 












C NMR spectrum of 4-(2-nitrophenyl)-4H-1,2,4-triazole (sm1) (101 MHz, DMSO-d6, 298 
K). 




H NMR spectrum of 1-benzyl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide
 
(10n) (400 






C NMR spectrum of 1-benzyl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide (10n) 




H NMR spectrum of 1-isopropyl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide (10o) 






C NMR spectrum of 1-isopropyl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide (10o) 




H NMR spectrum of 1-(but-3-yn-1-yl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide 






C NMR spectrum of 1-(but-3-yn-1-yl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide 




H NMR spectrum of 4-(2-nitrophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium 






C NMR spectrum of 4-(2-nitrophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium 




H NMR spectrum of 1-mesityl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium 






C NMR spectrum of 1-mesityl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium 




H NMR spectrum of 1-(4-methoxyphenyl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium 






C NMR spectrum of 1-(4-methoxyphenyl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium 




H NMR spectrum of 1-(4-fluorophenyl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium 






C NMR spectrum of 1-(4-fluorophenyl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium 




F NMR spectrum of 1-(4-fluorophenyl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium 






H NMR spectrum of 1-(4-chlorophenyl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 1-(4-chlorophenyl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium 






H NMR spectrum of 1-allyl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide (10v) (400 




C NMR spectrum of 1-allyl-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide (10v) (101 






H NMR spectrum of 1-(2-methylallyl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide 




C NMR spectrum of 1-(2-methylallyl)-4-(2-nitrophenyl)-4H-1,2,4-triazol-1-ium bromide 
(10w) (101 MHz, DMSO-d6, 298 K). 
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H NMR spectrum of 4-(2-ammoniophenyl)-1-benzyl-4H-1,2,4-triazol-1-ium chloride (11n) 




C NMR spectrum of 4-(2-ammoniophenyl)-1-benzyl-4H-1,2,4-triazol-1-ium chloride (11n) 






H NMR spectrum of 4-(2-ammoniophenyl)-1-isopropyl-4H-1,2,4-triazol-1-ium chloride 




C NMR spectrum of 4-(2-ammoniophenyl)-1-isopropyl-4H-1,2,4-triazol-1-ium chloride 






H NMR spectrum of 4-(2-ammoniophenyl) -1-(but-3-yn-1-yl)-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 4-(2-ammoniophenyl)-1-(but-3-yn-1-yl)-4H-1,2,4-triazol-1-ium 






H NMR spectrum of 4-(2-ammoniophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium chloride (11q) 




C NMR spectrum of 4-(2-ammoniophenyl)-1-phenyl-4H-1,2,4-triazol-1-ium chloride (11q) 






H NMR spectrum of 4-(2-ammoniophenyl)-1-mesityl-4H-1,2,4-triazol-1-ium chloride (11r) 




C NMR spectrum of 4-(2-ammoniophenyl)-1-mesityl-4H-1,2,4-triazol-1-ium chloride 






H NMR spectrum of 4-(2-ammoniophenyl)-1-(4-methoxyphenyl)-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 4-(2-ammoniophenyl)-1-(4-methoxyphenyl)-4H-1,2,4-triazol-1-ium 






H NMR spectrum of 4-(2-ammoniophenyl)-1-(4-fluorophenyl)-4H-1,2,4-triazol-1-ium 




C NMR spectrum of 4-(2-ammoniophenyl)-1-(4-fluorophenyl)-4H-1,2,4-triazol-1-ium 






F NMR spectrum of 4-(2-ammoniophenyl)-1-(4-fluorophenyl)-4H-1,2,4-triazol-1-ium 




H NMR spectrum of 4-(2-ammoniophenyl)-1-(4-chlorophenyl)-4H-1,2,4-triazol-1-ium 






C NMR spectrum of 4-(2-ammoniophenyl)-1-(4-chlorophenyl)-4H-1,2,4-triazol-1-ium 




H NMR spectrum of 1-allyl-4-(2-ammoniophenyl)-4H-1,2,4-triazol-1-ium chloride (11v) 






C NMR spectrum of 1-allyl-4-(2-ammoniophenyl)-4H-1,2,4-triazol-1-ium chloride (11v) 




H NMR spectrum of 4-(2-ammoniophenyl)-1-(2-methylallyl)-4H-1,2,4-triazol-1-ium 






C NMR spectrum of 4-(2-ammoniophenyl)-1-(2-methylallyl)-4H-1,2,4-triazol-1-ium 
chloride (11w) (101 MHz, DMSO-d6, 298 K). 




H NMR spectrum of 1-benzyl-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 






C NMR spectrum of 1-benzyl-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 




H NMR spectrum of 1-isopropyl-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 






C NMR spectrum of 1-isopropyl-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 




H NMR spectrum of 1-(but-3-yn-1-yl)-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 






C NMR spectrum of 1-(but-3-yn-1-yl)-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 




H NMR spectrum of 1-phenyl-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 






C NMR spectrum of 1-phenyl-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 




H NMR spectrum of 1-mesityl-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 






C NMR spectrum of 1-mesityl-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 




H NMR spectrum of 1-(4-methoxyphenyl)-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-






C NMR spectrum of 1-(4-methoxyphenyl)-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-




H NMR spectrum of 1-(4-fluorophenyl)-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 






C NMR spectrum of 1-(4-fluorophenyl)-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 




F NMR spectrum of 1-(4-fluorophenyl)-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 






H NMR spectrum of 1-(4-chlorophenyl)-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 




C NMR spectrum of 1-(4-chlorophenyl)-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 






H NMR spectrum of 1-allyl-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 




C NMR spectrum of 1-allyl-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 






H NMR spectrum of 1-(2-methylallyl)-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 




C NMR spectrum of 1-(2-methylallyl)-9H-benzo[4,5]imidazo[2,1-c][1,2,4]triazol-1-ium 
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